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1. Introduction 
Liquid Chromatography tandem Mass Spectrometry (LC-MS) is a powerful tool 
available for scientists. According to pubmed publications data collected from 
https://www.ncbi.nlm.nih.gov/pubmed/ using Liquid Chromatography Mass 
Spectrometry or LC-MS as input search, more than 130,000 results came out. 
Furthermore, the publications trend is keeping rising overcoming more than 8,400 
papers per year in the last five years. These data are the demonstration that LC-MS 
is increasing in terms of popularity in the scientific world. LC-MS is widespread in 
many scientific applications starting from chemistry to biology and much more.   
On these basis, in this introduction we will address the following topics: 
(1) From the born of chromatography to development of modern UHPLC system. 
(2) Mass spectrometer analyzers. 
(3) The coupling of liquid chromatography to mass spectrometry systems. 
(4) The main LC-MS applications in pharmaceutical analysis, bioanalysis and 
proteomics. 
1.1 Liquid Chromatography 
1.1.1 Liquid Chromatography (LC) 
The first paper published about chromatography was published by A. J. P. Martin 
and R. L. M. Synge on Biochemical Journal in 1941. In this paper, the concepts of 
chromatography and theoretical plates were described and applied, and it allowed 
them to win the Nobel prize in chemistry in 19521. Nevertheless, the inventor of 
chromatography is recognized as Mikhail S. Tswett, a Russian botanist who worked 
on the separation of plant pigments at the beginning of 19002. The first High 
Performed Liquid Chromatography (HPLC) apparatus was described by C. G. 
Horváth e S. R. Lipsky and B. A. Preiss with two papers published on Nature and 
Analytical Chemistry in 1966 and 19673,4, respectively. From those days to now, 
considerable progress has been made until the born of modern UHPLC.   
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The aim of Chromatography is to separate single components in a mixture relying 
on the adsorption and desorption equilibrium of each compounds between the liquid 
(mobile) phase and the solid (stationary) phase5. 
So, two adjacent compounds can be defined separated if their peaks result resolved 
and spaced at the peak bases. To evaluate and to improve the chromatographic 
resolution, van Deemter et al.6 proposed the following equation 1(1): 
 
 1 (1) 
 
1 (1) where: 
H is plate height, λ is particle shape (with regard to the packing), dp is particle 
diameter, γ, ω, and R are constants, Dm is the diffusion coefficient of the mobile 
phase, dc is the capillary diameter, df is the film thickness, Ds is the diffusion 
coefficient of the stationary phase, u is the linear velocity. 
Equation 1 (1) can be simplified as following in 1 (2): 
1 (2) 
1 (2) where: 
A is the Eddy diffusion, determined by the possible pathway of the mixture 
compounds which can go across the porous of the stationary phase causing peak 
broadening.  
B is the longitudinal diffusion of two adjacent compounds during the 
chromatographic elution. C is the resistance to mass transfer, which means all the 
possible chemical interaction between the mobile and stationary phases. 
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The van Deemter equation can be represented in the following plot (figure 1): 
 
Figure 1.  Van Deemter equations and plot of plate height(modified from Gross et al7) 
 
From van Deemter work, it is possible to determine the optimum flow rate to achieve 
the lowest height of H, allowing the best efficient chromatographic resolution for 
each chromatographic system.  
There are a lot of parameters that can be studied and optimized to improve a 
chromatographic separation, such as the peaks retention time, the selectivity, the 
robustness and column efficiency. 
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1.1.2 High Performance Liquid Chromatography (HPLC) sections and method 
development 
HPLC systems are constituted by mobile phase reservoirs, degasser, pumps, 
automated injector and autosampler, LC column, detector and PC as shown in figure 
2.  
 
Figure 2. Schematic design of an HPLC system (figure from waters, http://www.waters.com) 
 
All the HPLC compartiments are always object of research to provide to the scientists 
instruments with robustness, sensitivity, accuracy and precision performance 
updated and improved.  
Mobile phases, stationary phases, injection volume and detector setting values are 
the main parameters to be optimized during the method development.  
In both reversed phase LC and hydrophilic LC mobile phases are constituted by a 
lipophylic (e.g. methanol and acetonitrile) and polar  (e.g. water, saline buffers) 
solvents with or without pH modificators (e.g. formic or acetic acid and sodium 
hydroxide). A pH modificator can gain importance in LC tandem mass spectrometry 
system in modifying the compounds ionization before the MS analysis. 
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Stationary phases which characterized a chromatographic column are the key factors 
during the method development. Available on the market, there are essentially three 
kinds of column which differ each others for the structural features of the column 
packaging. They are: the monolits of second generation, the silica fully porous 
particles and the silica core shell particles.  
Focusing on the last two and more common kind of columns, both of them can have 
the silica functionalized with different chemical moieties (e.g. C18, C8, C4, C1, 
HILIC, cyano, phenyl, fluoro-phneyl, amino, amide and phenyl-hexyl) to allow 
different compounds partitions between mobile and stationary phases, with the 
possibility of taking advantages in term or resolution. Different silica 
functionalizations make different chemical interactions (e.g. hydrophobic, hydrogen 
binding, electrostatic, steric and π-π interaction) between column and analytes.  
Nevertheless, fully porous and core shell particles differ for the structure of the 
microsphere. For the first one, microspheres are made of a porous fully silica particle 
while for the core shell, the core is made by a solid silica sphere covered by a porous 
silica shell.  
For the fully porous, 100% of the surface can interact with the analytes, while in core 
shell this surface is limited for the shell, decreasing the number of theoretical plates. 
At the same time, a lot of advantages are provided by core shell particles compared 
to equal diameter fully porous one: increased permeability, reduced pore volume, 
reduced porosity, reduced van Deemter, A, B and C terms (the last one for 
macromolecules e.g. peptides) and the thermal conductivity is increased. All of these 
positive features made of the core shell a good alternative to fully the porous particles 
as column packing material for HPLC systems8,9,10,11,12,13,14.  
Despite these core shell advantages listed before, fully porous particles are still the 
golden standard in terms of column efficiency, resolution, productivity and 
robustness12,15. The real disadvantage of fully porous particles, which limit their use, 
is constituted by the huge backpressure generated, especially from the sub-2µm 
Chapter 1 
 
17 
 
particles. High backpressure forces these particles to Ultra-HPLC (UHPLC) 
instruments8.  
 
1.1.3 Ultra High Performance Liquid Chromatography (UHPLC) 
In the last line of the previous paragraph, it has been introduced the concept of 
UHPLC. The main difference between an UHPLC and HPLC analysis is in the 
backpressure managed by pumps. UHPLC pumps can work also over 1000 bar of 
pressure vs the 300 - 400 bar on HPLC instruments16,17. The impact of UHPLC with 
the use of sub-2µm particles size column was huge in different application fields18. 
To simplify the introduction of UHPLC system in laboratories, especially the 
pharmaceuticals of quality control, different protocols for transferring the HPLC 
methods on UHPLC were developed16. 
Finally, UHPLC operating with low micro and nanoflow rates are surely the last 
frontier in the liquid chromatography, especially for the analysis of large 
molecules19,20. 
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1.2 Mass Spectrometry (MS) 
Nowadays mass spectrometry is an indispensable tool, especially in R&D in so many 
disciplines. The first MS was built by J. J. Thomson (Nobel Prize for physics in 1906 
for electron discovery) who collected also the first MS spectra in 19097. From that 
day, we assisted to an outstanding growth of MS analyzers. At the state of the art, 
the most common MS are: the quadrupole, time of flight (TOF), magnetic sector (B), 
linear ion trap (LIT), QIT (quadrupole ion trap), Fourier transform ion cyclotron 
resonance (FT-ICR) and the orbitrap. 
Quadrupole, QIT and orbitrap are discussed in the next paragraphs. 
 
1.2.1 quadrupole (q) 
The quadrupole mass analyzer consists of four cylindrical (or even better hyperbolic) 
rod electrodes set perfectly parallel each other. As shown in figure 3, the rods have 
a z-direction and are mounted in a x, y plane configuration. 
 
Figure 3. Quadrupole geometry with hyperbolic rods and applied potentials21. Usually, quadrupoles have rods of 10-15 mm of 
diameter and a length of 15-25 cm. The radiofrequency is in the order of 1-4 MHz with voltages between 100-1000 V, providing 
also 100 ion oscillations per ion passage 
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The quadrupole principle of working is based on the use of an oscillating electric 
field to separate ions and so to stabilize ion trajectories at fixed m/z ratio. 
The pairs of opposite bars are each held at the same potential (Φ) which is composed 
of a DC and an AC component. Ions travel along the z axis and they are subjected to 
the influence of the electric field made by a quadrupolar alternative electric field 
superimposed to a constant electric field. This mechanism allows the m/z selection 
of ions of interest, excluding others that move out on x and y axis.  
This principle of action is explained from motions equation21.  
A way to evaluate the capability of a MS is the calculation of its resolving power or 
resolution (R). R is the ability of the MS analyzers to resolve to adjacent peaks and 
it is expressed by the following formula according to the peak width definition 1 
(3)22: 
1 (3) 
1 (3) where: 
R is the resolving power, m is the m/z of the peak ion, and Δm is peak width at the 
0.5 peak height. 
The resolution power of the quadrupole is unitary. It means that at 200 m/z, the 
resolving power is 2007. So, quadrupole is not considered a high-resolution analyzer. 
Nevertheless, considering the ability of the quadrupole as mass selector, it is 
common to see quadrupole series instruments applied for quantitative analysis (i.e. 
QqQ) or hybrid instruments such as Q-TOF, Q-FT-ICR or Q-LIT-orbitrap. 
 
1.2.2 quadrupole ion trap (QIT) 
A quadrupole ion trap (QIT) is based on the same principles of the quadrupole, even 
if the geometries of the analyzers differ. The QIT is constituted by two end caps that 
are hyperbolic electrodes, along with a ring electrode replaces the remaining two 
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rods of the quadrupole (figure 4). An open section between the r, y and z axis, is the 
inlet entrance for the ions. All components of the trap are structured to generate DC 
and RF potential between them. Due to these potentials, it is possible to set stable 
trajectories for ions in a set m/z range or of a fixed m/z, removing ions by leaving 
them to collide on the trap components or by axial ejection by instable trajectories.  
Another difference is made by the electric field generated in the trap. In fact, there is 
a three-dimension electric field, allowing 3D trajectories7. 
The motion equations of ions in the QIT are similar to the ones of quadrupole 
analyzer proposed by Mathieu and completed by Paul (Nobel Prize for physics in 
1989 for his work in developing MS analyzers23. 
According to Cooks et al.24, Ion traps resolution could reach 10000 at m/z 1000. It 
means that at 200 m/z, R is 2000, that it is not considered high resolution.  
 
Figure 4. QIT scheme (a) and its r and y section (b)25 
 
1.2.3 Orbitrap  
Orbitrap mass analyzer was described for the first time by Makarov in 200026, basing 
on Kingdon trap projects made in 1920s27. The first MS equipped with an orbitrap 
as first MS analyzer was introduced on the market by Thermo Fisher Scientific in 
200528.  The orbitrap is constituted by two parts: an external electrode with a shape 
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of barrel cut in two equal parts with a small interval, and a central electrode with a 
spindle shape. The maximum dimensions if the electrodes are 20 mm and 8 mm, 
respectively (figure 5). 
 
Figure 5. Orbitrap scheme design as proposed by Makarov26 
 
The orbitrap mechanism of action is resumed. Ions are injected from the ion source 
and trapped in the linear ion trap. Ions of interest can be isolated and fragmented in 
the linear ion trap, and even scanned out and detected by an independent set of 
detectors.  
To obtain high accuracy measurements, the ions are axially ejected from the linear 
trap into the c-trap where they are captured again and thermalized by collisions with 
nitrogen gas. Then, they are squeezed into a smaller cloud within the c-trap ready for 
injection into the orbitrap. 
When ions are into the orbitrap, the voltage on the central electrode increases and it 
forces the ion packages circling around the central electrode. 
Finally, ions come into the orbitrap lightly off axis and keep oscillating along the 
central electrode, until their stabilization 1 (4). The frequency of the harmonic axial 
oscillation (wz) is inversely proportional to the square root of m/z ratio of the ions 
(figure 6). 
1 (4) 
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1 (4) where: 
wz is the frequency of the harmonic axial oscillation, k is q is the ion charge and m is 
the ion mass.  
 
Afterwards, the image current is recorded on the outer split electrodes. The signals 
are amplified and transformed into a frequency spectrum by the fast Fourier 
Transform which is finally converted into a mass spectrum28. 
 
Figure 6. Orbitrap design scheme29 
 
The last orbitrap MS instrument released on the market from Thermo Fisher 
Scientific is the Orbitrap Fusion Lumos, an hybrid instrument which can reach a R 
(FWHM) value of 500,000 at 200 m/z (www.thermofisher.com). 
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1.3 Liquid Chromatography tandem Mass Spectrometry 
The first concept of electrospray ionization (ESI) was first described by Dole et al. 
and Taylor in the 1960s30,31. Only in the late 1980s, Mann et al32,33 applied this 
technique with success on molecules with a M.W. in the range of 100 - 2000 Da. 
Today, ESI is one of the most common ionization mode in LC-MS instruments. It is 
an ionization type belonging to class of atmospheric pressure ionization (API) 
methods, as the atmospheric pressure chemical ionization (APCI) and atmospheric 
pressure photoionization (APPI). ESI is the golden standard choice for liquid 
chromatography tandem mass spectrometry analysis, for either small and large 
molecules7. 
ESI together with matrix-assisted laser desorption/ionization (MALDI)34, another 
ionization mode, allowed the application of MS techniques also in biology for studies 
of large biomolecules. J. B. Fenn and K. Tanaka received the Nobel Prize in 
chemistry in 2002 for the development of soft ionization methods for mass 
spectrometric analyses of biological macromolecules35,36. 
 
1.3.1 ESI working concept 
 
Figure 7. ESI schematic design33 
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In ESI, the sample solution coming from a capillary tube at 1-20 μl min–1 of flow 
rate is ionized by applying an electric field at atmospheric pressure. The potential is 
applied by a cylindric electrode which surrounds the capillary tube, to guarantee an 
ionization at 3-6 kV. At this point, there is a charge accumulation on the liquid 
surface at the end of the capillary, which will be broken to form highly charged 
droplets once left in the space. Then, the droplets aerosol just formed pass into a 
countercurrent stream of hot inert nitrogen gas at low flow rates, as a heat source for 
supplying the complete solvent evaporation.  
A small portion of the sprayed material comes into the aperture of a transfer capillary 
(4-8 cm length with an internal diameter of 0.2 mm) at 102 Pa of pressure. A minor 
portion passes through the orifice of a skimmer (a cone-shaped electrode named 
Taylor cone, with a small aperture at its end) into the high vacuum behind (10–3 and 
10–4Pa). Finally, desolvation of the ions is completed and they are focused into a 
mass analyzer. A general scheme of the ESI is reported in figure 7. 
The potentials applied to the electrode, capillary, skimmer, and lenses behind provide 
an effective transfer of ions through the interface. These parameters are optimized 
depending of chemical features of the molecules to be ionized. 
The ions obtained from large molecules carry a greater number of charges if several 
ionizable sites are present (multicharged ions). Typically, a protein has one charge 
per thousand Da approximately. Small molecules with a M.W. lower than a thousand 
Da, will produce mainly monocharged ions. ESI can also be used in the case of 
molecules without any ionizable site through the formation of sodium, potassium, 
ammonium, formate, acetate or other adducts. However, ions have to be already 
present is sample solution before the electrospray ionization.  
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1.3.2 ESI application to different LC flow rates 
Nowadays, ESI is suitable of working at different flow rate from 50-200 μl min–1 for 
chemical and bioanalytical LC-MS applications to 200-400 nl min–1 for proteomics 
applications. 
 
For micro flow rate, the ESI has been assisted with the use of a nebulizer or sheath 
gas flow that provides a pneumatic assistance during the spray capillary process37,38. 
This improvement allows the use of higher sample solution flow rate reducing the 
surface tension of the solvent and providing its complete evaporation.  
 
At the same time, working with nano flow rate requires a nano ionization source and 
a nanoESI is essential for the optimal ionization of highly polar solutions. Both these 
two factors are common in the analysis of peptides in proteomics LC-MS based 
works. The nanoESI has been described by Wilm and Mann39, modifying the 
capillary spray structure of the electrospray. The spray needle is replaced with a 
borosilicate glass capillary with a narrow tip terminal of few μm of i.d. Lower 
droplets size are produced, and the sample consumption is reduced39,40. The spray 
voltage applied to the counter electrode is less than 1.5 kV. A micromanipulator 
working in three dimensions and a camera are necessary to set a correct distance of 
about 1 mm between the capillary and the entrance in the source.  
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1.4 LC-MS applications 
1.4.1 Pharmaceutical Analysis 
LC-MS technique is widespread in pharmaceutical analysis. There are a lot of 
applications in which LC-MS is involved, among them: determination of 
pesticides41,42, dose formulation analysis43, ADME studies44, impurity profiling45, 
toxicity studies46,47, quality assurance and quality control methods48, therapeutic 
drug monitoring49 and forced degradation studies14,50,51. In this paragraph, the forced 
degradation studies and the identification of the stability indicator of a drug will be 
discussed. This research field is regulated by the International Conference of 
Harmonization (ICH) guidelines Q1(A)R2 stability testing of new drug substances 
and products52. These guidelines report an overview on how to perform a validated 
stability study in case of drugs to be used for humans. Nevertheless, the experimental 
conditions are not detailed described, and the chemist has to set them up depending 
on the features of individual drug substances. 
The stress testing conditions aim to identify degradation products arising from drug 
substances, to establish a degradation pathway and to study the intrinsic stability of 
the compounds evaluated. The forced conditions studied usually include natural, 
acidic, alkaline, oxidative, the presence of a radical initiator and photodegradation in 
both daylight and UV light. Time points are dependent to concentrations involved to 
each stress reactions and they are fixed from few hours to 48 hours until 14 days for 
daylight photodegradation exposure. Also, the temperature is a key feature to be 
examined and it is set for all conditions between room temperature and 50°C. 
After planning the protocol with the stress testing condition, it is common to develop 
an LC-MS method for the identification of the drug substances and of the degradation 
products that could be developed during the experimental conditions. 
A linear gradient covering all the percentages of the organic mobile phase is the 
golden standard strategy during the LC-MS method optimization. It is an important 
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aspect to be evaluated, considering that the nature on the possible degradation 
products is unknown in the early stages of the stability testing. Other LC-MS 
parameters are set on drug substances.  
Once a product degradation product is identified, full MS, MS2 and MS3 spectra are 
studied to propose a structure and so for the identification. Orthogonal techniques to 
mass spectrometry are necessary such the nuclear magnetic resonance (NMR) and 
the infrared spectroscopy (IR) for the complete characterization.  
The following step is the production of the degradation compounds in order to have 
them pure to compare the results obtained during stress studies. This is essential to 
confirm and to validate the degradation pathway of drug substances.  
Examining degradation products under stress conditions is useful also in developing 
and validating suitable analytical procedures for stability studies of drug products. 
In fact, the degradation compounds identified could be formed during the life of a 
pharmaceutical products. 
At the same time, ICH Q2 (R1) guidelines are followed to validate an analytical 
method suitable for stability analyses in pharmaceutical field53. The parameters 
investigated for the method validation are: the selectivity, robustness, lower limit of 
detection (LOD) and lower limit of quantification (LOQ), linearity, intraday and 
interday precision and accuracy14. 
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1.4.2 Bioanalysis 
Bioanalyses are described as the identification or quantification of analytes in 
biological samples (e.g. tissue culture, blood, plasma, serum, urine, feces and saliva) 
coming from different species. Analytes are either large (e.g. proteins and peptides) 
and small molecules (e.g. metabolites and drugs). The applications are numerous: 
molecular biology, clinical and preclinical, pharmacokinetic, pharmacodynamic and 
toxicology studies. Different apparatus can be employed for performing bioanalysis. 
In this paragraph, it will be discussed bioanalysis carried out with LC-MS 
instruments.  
 
1.4.2.1 Sample preparation techniques 
Sample preparations are different approaches performed before the LC-MS analysis, 
to clean and to purify the biological samples from salts and other molecules which 
could interfere with the ionization and detection of the analytes. Considering that the 
biological samples are complex mixtures made of proteins, lipids, small polar 
compounds, the extraction of the analytes of interest is a key step in bioanalysis. The 
main methodologies are the following: 
(1)  Protein precipitation (PPT): it consists in the adding of organic solvents (e.g. 
acetonitrile, methanol or acetone), pH modulator (trichloroacetic and perchloric 
acids) and metal ions (e.g. zinc salts). PPT is one of the most common techniques14,54, 
quick, easy to do, not expensive, with high ion suppression and good sensitivity. It 
is suitable for the extraction of both polar and hydrophobic compounds. 
(2) Liquid liquid extraction (LLE): it is used for liquid biological samples (e.g. 
plasma55, serum56 and urine57) which are mixed with organic solvents. This 
technique is common for acidic of basic drugs. Often, LLE and PPT are coupled with 
an evaporation step to concentrate the analytes before the LC-MS analysis. The LLE 
96-well plates automation has been a key upgrade of this technique, solving the 
mixing issues58,59. 
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(3) Solid phase extraction (SPE)60: it is often the first choice in the analytical labs 
due its high reproducibility and efficiency. SPE consists in the loading of the sample 
upon few centimeters of sorbent cartridge. It is functionalized in different ways 
offering numerous types of interactions between the stationary phase and the 
analytes to be extracted. Washing and an elution steps are required during the 
extraction process. SPE negative points are the time consuming either during the 
method development and the sample handling in routine analysis. Positive aspects 
are the preconcentration of the biological samples and the automation with online 
methods which guarantee a reliable, robustness and time saving in this step of the 
analysis61. 
Moreover, it is a recent trend, the miniaturization of some sample preparation 
methodologies such as the SPE. This approach allows low sample consumption, less 
volume of solvents is required with same effectiveness of the “classic” methods62,63. 
 
1.4.2.2 LC-MS bioanalytical method parameters 
Some LC-MS method parameters must be evaluated and measured during the 
method development phase. Handling biological matrices mean working with a lot 
of biological interferences that could vary the detection of the compounds of 
interests.  Hence, the evaluation of the LC-MS parameters guarantees the quality and 
the robustness of the bioanalysis. The parameters are: selectivity, linearity, precision, 
accuracy, matrix effect, recovery, stability and sensitivity64. 
(1) The selectivity is the ability of the bioanalytical method to measure and 
differentiate the analytes in the presence of components that may be expected to be 
present. These could include metabolites, impurities, degradants, or matrix 
components. It is evaluated by injecting a matrix blank sample coming from different 
sources. The aim is to exclude interferences peaks with analytes at lower limit of 
quantification (LLOQ) concentration. To do that, the signal to noise (S/N) ratio is a 
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useful system suitability parameter. The S/N ratio is calculated as follow as described 
on U. S. Pharmacopeia (621): 
S/N ratio =  2H/h  1(5) 
1 (5) where: 
H is the height of the peak measured from the peak apex to a baseline extrapolated 
over a distance ≥5 times the peak width at its half-height; and h is the difference 
between the largest and smallest noise values observed over a distance ≥5 times the 
width at the half-height of the peak. 
 
(2) The linearity is evaluated for quantitative methods with the internal or the 
external calibration method, depending on the diluting solutions (matrix or solvents, 
respectively) used for preparing the calibration points. 6-8 points are suggested for 
rough calibration curves included a blank sample (with n=5 of repeatability). A 
calibration curve has to be prepared fresh before each batch analysis. 
(3) The precision is the closeness of agreement between a series of measurements 
obtained from multiple sampling of the same homogenous sample under the 
prescribed conditions. It is evaluated at least on three levels (LLOQ, MQ and HQ), 
n=5. Precision is evaluated intrabatch and interbatch.  
(4) The accuracy is the degree of closeness of the determined value to the nominal 
or known true value under prescribed conditions. This is sometimes termed trueness. 
It is evaluated on three different levels (LLOQ, MQ and HQ), n=5. It is calculated 
with following formula. 
 
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =
Observed conc−Nominal conc
Nominal conc
× 100    1(6) 
(5) The matrix effect is the direct or indirect alteration or interference in response 
due to the presence of unintended analytes (for analysis) or other interfering 
substances in the sample. While, the recovery is the extraction efficiency of an 
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analytical process, reported as a percentage of the known amount of an analyte 
carried through the sample extraction and processing steps of the method. 
To measure the matrix effect (ME) and the recovery (RE), three samples are 
prepared:        
-A: analyte in solvent; 
-B: analyte added to the matrix after the extraction procedure; 
-C: analyte added to the matrix before the extraction procedure. 
 
% ME is calculated as: 
% 𝑀𝐸 =
𝐵
𝐴
 × 100     1 (7) 
Moreover, matrix effect could be evaluated also with a qualitative method when a 
blank matrix (without analytes) is available65. 
% RE is calculated as:  
% 𝑅𝐸 =
𝐶
𝐵
 × 100     1 (8) 
(6) The stability could be evaluated with four different assays: freeze and thaw 
stability, short term temp stability (between 4-24 h), long term stability (between 20 
to 60 days), stock solution stability and post preparative stability. 
(7) The sensitivity is evaluated as: limit of detection (LOD, the lowest concentration 
of an analyte that the bioanalytical procedure can reliably differentiate from 
background noise) and the lower limit of quantification (LLOQ, the lowest amount 
of an analyte in a sample that can be quantitatively determined with suitable precision 
and accuracy). 
 
In general, CV values are retained satisfactory when ≤ 15% or ≤ 20% for LLOQ. 
While for % ME and % RE there are not reported values, but it is suggested to reach 
percentages closest to 100%.  
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1.4.3 Proteomics 
1.4.3.1 Introduction 
Proteomics as word was born in the middle of nineties as the fusion of protein and 
genomics66,67. The proteomics general aim is the identification and characterization 
of the whole proteome of all the organisms68. Moreover, to understand the protein 
sequencing, protein post translational modifications (PTMs), protein localization, 
protein quantification and protein-protein interactions are even more challenging 
than a genome identification69,70. By the years, proteomics grew up becoming a new 
discipline across chemistry and biology. The proteomics backbone is constituted by 
the mass spectrometry (MS), sample preparation and bioinformatic data analysis. 
Each of these aspects must be accurately planned in order to achieve the results 
required.  
 
1.4.3.2 Proteomics approaches 
An LC-MS based proteomic analysis may be performed on biological samples 
constituted by intact proteins or enzymatically digested proteins into peptides. So, 
depending on the approach chosen, the strategies available are essentially three: top 
down, bottom-up and shotgun. 
The first one, top down proteomics means that proteins are analyzed as intact entities 
without any proteolysis. The main advantages of this approach are determined in the 
study of PTMs, in the sequence coverage and in protein quantitation. However, there 
are some limitations, such as the limited fragmentation of intact protein in the gas 
phase, protein front-end separation is challenging, and it is applicable only for pure 
protein or small protein mixtures. All these disadvantages, make this approach quite 
far from the routine analysis.  
Secondly, bottom up proteomics is the characterization of proteins after their 
enzymatically digestion into peptides prior the MS analysis. While, Yates lab.71 
coined the term shotgun proteomics referring to bottom up proteomics performed on 
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complex protein mixture. With the shotgun proteomics all the disadvantages of the 
top down proteomics are overcome. However, peptides identification is a key point 
and it is achieved by the overlapping of the peptides MS2 spectra generated from the 
LC-MS analysis with the ones generated from the in silico digestion of the 
appropriate protein database. Furthermore, the peptide identified is assigned to the 
protein (if single so uniquely associate to only one protein) or proteins which shared 
that peptide. The identification is regulated by search criteria and scoring schemes 
and it is usually followed by the filtering of the results evaluating the false discovery 
rate 29,69,72,73,74.  
The following paragraphs will be focused on shotgun proteomics. 
 
1.4.3.3 Ionization, fragmentation and acquisition mode 
In shotgun proteomics, two types of soft ionization techniques in are commonly used, 
able to perform the ionization of peptides. They are the nanoelectrospray (nESI) and 
the matrix-assisted laser desorption/ionization (MALDI)75,76,. In general, nESI is 
used for peptides in solution, so it is coupled with UHPLC instruments working with 
nano- or low-micro flow rates, while MALDI is involved for gel based matrix or 
tissue samples.  
After the sample ionization, another key point is the fragmentation mode, essential 
to generate MS2 spectra of peptide ionized. The first one to be developed and applied 
for peptides fragmentation was the collision induced dissociation (CID). In low 
energy CID, b- and y- fragment ions are generated (backbone C-N bond broken), due 
to multiple collisions with rare gas atoms to the ion peptide positively charged. A 
modification of CID technique is the higher-energy collisional dissociation (HCD). 
It is specific for orbitrap and hybrid instruments and it takes place external to the ion 
trap (e.g. HCD cell)77. HCD is considered one of the most used fragmentation 
methods due to its applicability also for PTMs studies. Another technique was 
introduced by MacLafferty lab in 199878,79 and it is called electron-capture 
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dissociation (ECD). It consists in the capture of a thermal electron by peptides 
positively charged inducing a N-Cα backbone fragmentation generating c- and z- 
type fragment ions. It allows to produce more product ions in the peptide MS2 than 
CID and HCD, getting a better sequence coverage and a good PTMs identification 
in comparison with CID and HCD. Finally, one more fragmentation methods is 
represented by the electron-transfer dissociation (ETD), developed by Hunt lab. in 
200480. It is similar to the previous one in producing essentially c- and z- type 
fragment ions. In fact, ETD induces fragmentation of large, multiply-charged cations 
by transferring electrons to them from radical anions with low electron affinity. It 
provides fragmentations with femtomole of peptides due to the fast and efficient 
mechanism of generating MS2 product ions. With this technique, there is the 
increasing of sequence coverage. PTMs are left intact during the fragmentation 
making this fragmentation technique the golden standard for these analyses. 
Unlucky, ECD and ETD are relegated essentially on ions trap, FTICR and hybrid 
expensive instruments (figure 8).  
In conclusion, the CID/HCD fragmentation mode are the most common and the most 
used in proteomics LC-MS based analysis. 
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Figure 8. MS fragmentation techniques applied in proteomics69 
 
While, another theme faced in the last period is about the acquisition mode in 
proteomics analysis.  There essentially two acquisition modes: the data dependent 
acquisition (DDA) and the data independent acquisition (DIA)81. DDA consists in 
the acquiring a full MS spectrum of the peptides (MS1), followed by the collection 
of as many fragmentation spectra (MS2) as possible, within a cycle time of about 1 
second (time window is variable). It is common to find methods with the selection 
of the top 12 MS1 peptide ions fragmentated to design the MS2 spectra per cycle. 
While, DIA is constituted by sequential windows of acquisition made usually of 25 
m/z units, in which all the MS1 ions identified are selected, fragmented and acquired 
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by the MS detector. DIA MS2 spectra are really complex and specific deconvolution 
and identification software are required for the data analysis81,82,83. 
Another acquisition technique used in proteomics even if not widespread in this field 
is the single reaction monitoring mode (SRM). It is common in triple quadrupoles 
instruments (QqQ) or in ion traps for quantitative analysis. SRM finds proteomics 
applications in ion traps and orbitrap instruments for quantitative analysis of targeted 
peptides.  
Theoretically, DIA should include both the advantages of DDA and SRM modes82. 
 
1.4.3.4 Mass Spectrometry instruments for proteomics 
To perform LC-MS based proteomics analysis is essential to have a high-resolution 
mass spectrometer. Mass analyzers that can provide high resolution analysis are: 
FTICR, TOF and Orbitrap trend by mass spectrometers producers to configure 
hybrid instruments to improve mass accuracy, sensitivity and resolution. The main 
configurations found in proteomics are: LTQ-Orbitrap, Qq-Orbitrap, LTQ-FTICR, 
QqQ-FTICR, Q-TOF and IT-TOF29.  
 
1.4.3.5 Starting material and sample preparation for shotgun proteomics 
For shotgun proteomics analysis, the starting material could be different and coming 
from various origin. Usually, the principle biological matrices are analysed such as 
biological fluids, cells and tissue. The development of working protocols is a key 
point of the proteomics. Focusing on the analysis of the intracellular content, some 
sample preparations steps and tips are maintained. So, proteins were extracted after 
cells culture and then lysed. Afterwards, proteins extracted were firstly reduced to 
break disulphide bonds, and then alkylated to reduce the sulfhydryl free moieties. 
The lest steps are the proteins digestion into peptides and the sample desalting before 
the injection in the LC-MS84,85,86. 
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1.4.3.6 Bioinformatics 
As previously mentioned in 1.4.3.2 section, bioinformatics tools are gaining 
popularity and are still under development to make data analysis reproducible, easy 
to do and accurate. Since the publication of SEQUEST in 199487, a software for the 
protein identification from peptides mixture, numerous other algorithms were 
published (88,89,90). However, the integration of software packages into pipelines 
helped the scientists to standardize and simplify the proteomics analysis workflow. 
Nowadays, there are various pipeline, by which: Proteomics Pipeline (IP2, 
http://integratedproteomics.com/), pFind Studio (http://pfind.ict.ac.cn/)91,92, 
ProteomeDiscoverer (www.thermoscientific.com), MaxQuant 
(http://maxquant.org/)93. A representative pathway of data acquisition and 
bioinformatic data analysis pathway is reported in figure 9. 
 
Figure 9. Representative LC-MS/MS data acquisition and bioinformatic data analysis pipeline for protein identification and 
quantification in shotgun proteomics69 
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2. Outline of the thesis 
Especially in the last 25 years, a lot of efforts and investments were made in R&D 
to develop new LC-MS components and instruments. The huge adaptability of the 
technique and the unlimited applications of the LC-MS, pushed the scientists in the 
pathway of breaking limits and achieving new records. 
In this context, the main aim of the thesis was to show the versatility of LC-MS in 
the chemistry and biology research. LC-MS was applied in medicinal chemistry for 
degradation studies of active compounds, in quantitative bioanalysis of small 
molecules in plasma, intracellular and extracellular compartments and in proteomics 
to study post translational modifications.  
To perform all of these LC-MS analyses different instruments were used, suitable to 
achieve the results required. 
The liquid chromatography instrument used were HPLC and UHPLC systems 
equipped with quaternary pumps operating with micro- and nano-flow rates. Mass 
Spectrometry ion source was constituted by the electrospray ion source (ESI) or by 
the nano-ESI. Moreover, MS detectors were constituted by a linear ion trap, or an 
hybrid instrument constituted by a quadrupole, linear trap and orbitrap.  
The instruments were working in both positive and negative ionizations mode with 
different scans type: full MS, MS2, MS3, SRM (Single reaction monitoring), MRM 
(Multiple Reaction Monitoring) and DDA (Data Dependent acquisition) mode. 
Fragmentations method involved were CID (Collision Induced Dissociation) and 
HCD (Higher-energy Collisional Dissociation). 
In these three working years, the LC-MS tool was applied to the following projects:  
(1) Investigation of troxerutin (TRX) degradation pathway, degradation products 
characterization and identification of TRX stability indicator.  
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(2) Development of a bioanalytical LC-MS method for the quantification of 
adenosine 5’-tetraphosphate (Ap4) and other five analytes related to Nicotinamide 
phosphoribosyltransferase (NAMPT) metabolism in different biological matrices. 
(3) Development of a quantitative LC-MS bioanalytical method for the quantitation 
of serotonin extracellular levels of murine neural progenitor cells. 
(4) Identification, quantification and investigation of post-translational 
modifications (PTMs) on Nicotinamide phosphoribosyltransferase (NAMPT) in 
murine melanoma B16 cells. 
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Abstract: 
Troxerutin (TRX) is a mixture of semisynthetic hydroxyethylrutosides (Hers) arising 
from hydroxyethylation of rutin, a natural occurring flavonoid. TRX is commonly 
used for its anti-oxidant and anti-inflammatory properties in chronic venous 
insufficiency and other vascular disorders. In recent studies, the protective effects of 
TRX in Alzheimer’s disease, colon carcinogenesis and hepatocellular carcinoma are 
emerged. However, the chemical stability of TRX has never been studied. Hence, 
the aims of the work were to study the TRX chemical stability through a forced 
degradation study and to develop and validate a new stability indicating LC-UV 
method for determination of TRX. In order to perform the study, TRX stability was 
tested in various stress conditions analysing the degradation samples by LC–MS. 
Three degradation products (DPs; D1, D2 and D3, 3’,4’,7-Tri-O-(β-
hydroxyethyl)quercetin, 3’,4’,5,7-Tetra-O-(β-hydroxyethyl)quercetin and 3’,4’-Di-
O-(β-hydroxyethyl)quercetin respectively) arising from degradation in acidic 
conditions were identified and synthesized: among them, D1 resulted the stability 
indicator for hydrolytic degradation. Furthermore, a stability-indicating LC-UV 
method for simultaneous determination of triHer (3’,4’,7-Tri-O-(β-
hydroxyethyl)rutin, the principal component of the mixture) and D1 was developed 
and validated. The LC-UV method consisted in a gradient elution on a Phenomenex 
Kinetex EVO C18 (150 × 3 mm, 5 µm) with acetonitrile and ammonium bicarbonate 
buffer (10 mM, pH 9.2). The method was linear for triHer (20–60 µg mL−1) and D1 
(5.1–35 µg mL−1). The intraday and inter-day precision were determined and 
expressed as RSDs: all the values were ≤ 2% for both triHer and D1. The method 
demonstrated also to be accurate and robust and the average recoveries were 98.8 
and 97.9% for triHer and D1, respectively. Moreover, the method resulted selective 
and specific for all of the components present in the degradation pattern of TRX 
(diHer (3’,4’-Di-O-(β-hydroxyethyl)rutin), triHer, tetraHer (3’,4’,5,7-Tetra-O-(β-
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hydroxyethyl)rutin), D3, D1 and D2) and it was successfully applied for the stability 
studies of both drug substances and drug products. 
1. Introduction: 
Troxerutin (TRX) is a mixture of semisynthetic O-hydroxyethylrutosides (Hers), 
arising from hydroxyethylation of rutin1, a natural occurring flavonoid mainly 
extracted from Dimorphandra gardneriana2 and Sophora japonica3. As reported in 
the European Pharmacopoeia4, TRX contains minimum 80% of 
tris(hydroxyethyl)rutin as the principal component, while 
tetrakis(hydroxyethyl)rutin, bis(hydroxyethyl)rutin and mono(hydroxyethyl)rutin 
are also described as related components present in minor amount. In therapy, TRX 
is currently used against sign and symptoms of chronic venous insufficiency and 
other vascular disorders such as hemorrhoids, microangiopathy and diabetic 
retinopathy, also displaying effectiveness and safety in elderly patients and pregnant 
women. TRX acts mainly on the microvascular endothelium by means of its anti-
oxidant and anti-inflammatory properties reducing hyperpermeability, edema and 
improving microvascular perfusion and microcirculation5–8. Furthermore, recent 
studies proposed TRX as a promising agent with neuroprotective effects on cognitive 
deficits9, in Alzheimer’s disease10 and in Parkinson’s disease11. Besides a number of 
other beneficial effects have been highlighted, such as the chemoprevention in colon 
carcinogenesis12, hepato-cellular carcinoma13 and as adjuvant with 5-Fluorouracil in 
gastric cancer14, a potential role against neuropathic pain15, cardioprotective and 
antifibrogenic effects16,17, its use as adjuvant in radiotherapy to protect normal 
tissues18 and in the reduction of the severity of myocardial ischemia-reperfusion 
injury19. As a matter of fact, despite the lots of recent published in vitro and in vivo 
studies establishing new potential biological properties of this drug, TRX is always 
reported as triHer single isomer (3’,4’,7-tris(hydroxyethyl)rutin), without 
considering the presence, in the mixture, of the other Hers20–23. At the best of our 
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knowledge, the literature reports very few papers dealing with the characterization 
of TRX related compounds, whose number can theoretically reach fifteen24,25; 
moreover, none deals with the chemical stability of TRX. This is probably due to the 
fact that TRX composition depends on the synthetic strategy and on the difficulties 
in the chromatographic separation of this mixture26. In this complex scenario, the 
aims of the present study were first to establish the intrinsic chemical stability of a 
batch of TRX through a forced degradation study in parallel with the characterization 
both of the principal pure isolable Hers and their degradation products (DPs); 
secondly to develop and validate a new LC-UV stability indicating method for the 
simultaneous quantification of TRX as its major component triHer and its stability 
indicator, D1. 
2. Experimental: 
2.1. Reagents and chemicals 
Acetonitrile (HPLC grade), ammonium bicarbonate, 25% ammonia solution, sodium 
hydroxide, dimethyl sulfoxide, 30% w/w hydrogen peroxide solution, hydrochloric 
acid, sodium borohydride, 4,4_-azobis(4-cyanopentanoic acid), methanol, 
tetrahydrofuran, ethyl acetate, isopropanol, acetic acid, pyridine-d5,dichloromethane, 
potassium bromide, ascorbic acid, titanium dioxide, gum arabic, corn starch, talc, 
polivinylpyrrolidone (PVP), colloidal silica, magnesium stearate, calcium carbonate, 
kaolin, orange yellow (E110), indigotine (E132), sucrose, sodium chloride were 
purchased from Sigma-Aldrich (Milano, Italy); silica gel 60 (0.040-0.063 mm) 
purchased from Merck (Darmstadt, Germany).Water (HPLC grade) was obtained 
from Milli-Q RO system. Carbazochrome (lot n° CA-073-03) was obtained as gift 
sample from Pharmafar S.r.l. (Torino, Italy). Batches of Troxerutin (TRX, batches 
n°: 335539190, 33553C024, 33553T164), were kindly gifted by Acarpia (Torino, 
Italy). Venolen® capsules (batch n° 120054), Fleboside® ampoules (batch n°A107) 
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and Fleboside® coated tablets (batch n° A0711) were purchased from local 
pharmacy. 
 
2.2. Purification of Hers from TRX, synthesis of DPs and spectroscopic 
characterization 
2.2.1. Purification of Hers from TRX 
TRX was purified by silica gel column chromatography. The mobile phase consisted 
in a mixture of ethyl acetate-isopropanol-water-acetic acid (7:2:1:0.5, v/v/v/v) up to 
complete elution of diHer and triHer, then with ethyl acetate-isopropanol-water-
acetic acid (5:4:1:0.5, v/v/v/v) to complete elution of tetraHer. The purification of 6 
g of TRX gave: diHer (0.117 g, 2% yield, HPLC purity (254 nm): 63%, ESI-MS m/z 
699 [M+H]+ calculated for C31H38O18), triHer (1.635 g, 28% yield, HPLC purity (254 
nm): 94%, ESI-MS m/z 743 [M+H]+ calculated for C33H42O19), and tetra-Her (0.555 
g, 9% yield, HPLC purity (254 nm): 88%, ESI-MS m/z 787 [M+H]+ calculated for 
C35H46O20). 
 
2.2.2. Synthesis of degradation products 
2.2.2.1. 3’,4’,7-Tri-O-(β-hydroxyethyl)quercetin (D1)  
TriHer (3’,4’,7-Tri-O-(β-hydroxyethyl)rutin, 50 mg) was dissolved in 2 M HCl 
acqueous solution (2.5 mL). The solution was refluxed at90◦C for 90 min and the 
formation of a precipitate was observed. At the end of the reaction, (monitored by 
TLC: ethyl acetate-isopropanol-water-acetic acid 7:2:1:0.5, v/v/v/v), the mixture was 
filtered under vacuum to collect the precipitate. 25 mg of D1 were obtained (88% 
yield). HPLC purity (254 nm): 97.5%; ESI-MS m/z 435 [M+H]+ calculated for 
C21H22O10. 
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2.2.2.2. 3’,4’,5,7-Tetra-O-(β-hydroxyethyl)quercetin (D2) 
TetraHer (3’,4’,5,7-Tetra-O-(β-hydroxyethyl)rutin, 50 mg) was dissolved in 2 M 
HCl acqueous solution (2.5 mL). The solution was refluxed at 90°C for 90 min. At 
the end of the reaction (monitored by TLC: ethyl acetate-isopropanol-water-acetic 
acid 7:2:1:0.5, v/v/v/v), the solvent was evaporated under reduced pressure. The 
crude product was purified by silica gel column chromatography using 
dichloromethane-methanol (98:2, v/v) mixture as eluent to give pure D2 (29.9 mg, 
90% yield). HPLC purity (254 nm): 88.7%; ESI-MS m/z 479 [M+H]+ calculated for 
C23H26O11. 
 
2.2.2.3. 3’,4’-Di-O-(-hydroxyethyl)quercetin (D3)  
DiHer (3’,4’-Di-O-(β-hydroxyethyl)rutin, 75 mg) was dissolved in 2 M HCl aqueous 
solution (2 mL). The solution was refluxed at 90◦C for 90 min. At the end of the 
reaction (monitored by TLC: ethyl acetate-isopropanol-water-acetic acid 7:2:1:0.5, 
v/v/v/v), the solvent was evaporated under reduced pressure. The crude product was 
purified by silica gel column chromatography using dichloromethane-methanol 
(95:5, v/v) mixture as eluent to give pure D3 (38 mg, MW: 390.3, 90%yield). HPLC 
purity (254 nm): 95%; ESI–MS m/z 391 [M+H]+ calculated for C19H18O9. 
 
2.2.2.4. 1H and 13C NMR analyses 
1H and13C experiments were performed on a JEOL Eclipse ECP 300 FT MHz 
spectrometer (Jeol Ltd. Tokyo, Japan) operating at 7.05 T. Chemical shifts are 
reported in part per million (ppm). The spectra were collected in d6-DMSO (triHer, 
diHer and tetraHer) and in d5-pyridine (D1, D2 and D3). 
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2.3. Forced degradation study 
2.3.1. Stress studies 
Stress studies were carried out on TRX solution at a concentration of 1 mg mL-1. For 
acidic degradation study TRX was dissolved in 1 N HCl and the solution was left in 
the dark at room temperature and 50°C for 4 h and 24 h. The degradation in alkaline 
conditions was done in 1 N NaOH and the solution was left in the dark at room 
temperature and 50°C for 4 h and 24 h. To test the stability in neutral solution, TRX 
was dissolved in water and left at room temperature or at 50°C for 4 h, 24 h and 48 
h. For oxidative conditions, the degradation was performed in a 5% hydrogen 
peroxide solution and it was left in the dark at room temperature for 4 h, 24 hand 48 
h. The degradation with radical initiator was done dissolving TRX in 5 mM 4,4_-
azobis(4-cyanopentanoic acid) aqueous solution and it was left in the dark at room 
temperature for 24 h and 48 h. Photodegradation studies were carried out, at room 
temperature, by exposing a thin layer (5 mg) of TRX to daylight and UV-light (365 
nm) for 14 days and 4 h, respectively. Before LC-MS analyses, acidic and alkaline 
samples were firstly neutralized by addition of a suitable amount of NaOH and HCl, 
respectively, and then diluted by adding an appropriate volume of mobile phase. The 
samples arising from other stress conditions were analysed at 0.25 mg mL-1 after 
dilution with mobile phase. For comparison purposes, a freshly prepared aqueous 
solution of TRX was diluted at 0.25 mg mL-1 and analysed as above. The forced 
degradation study, restricted to the acidic conditions, was performed also on the 
purified diHer, triHer and tetraHer derivatives. 
 
2.3.2. MS and LC–MSn analysis 
A Thermo Finningan LCQ Deca XP Plus system equipped with a quaternary pump, 
a Surveyor AS autosampler, and a vacuum degasser was used for LC-MS analysis 
(Thermo Electron Corporation, Waltham, MA, USA). The flow injection analysis of 
the TRX solution (1 µg mL-1, CH3CN:H2O 50:50, v/v) before degradation was done 
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in positive ionization at a flow rate of 5 µL min-1. The LC-MSn analyses were 
performed on a Phenomenex Gemini NX C18 (100 x 2 mm I.D., 3 µm dp) column 
as a stationary phase maintained at 25°C. The mobile phase (flow rate: 0.2 mL min-
1) was composed of eluent A: ammonium bicarbonate buffer (10 mM, pH 9.2) and 
eluent B: CH3CN using the following gradient elution: after 10 min of 17% solvent 
B, it was increased up to 25% in 5 min and then maintained for other 5 min. Then, 
solvent B was decreased in0.5 min to 17% and maintained for 7.5 min for the 
equilibration. The total run time was 28 min. The sample injection volume was 5µL. 
The eluate was injected into the electrospray ion source (ESI) and the MS and MSn 
spectra were acquired and processed using the Xcalibur® software (Thermo Electron 
Corporation). The operating conditions of the ion trap mass spectrometer in positive 
ion mode were the following: spray voltage, 5.00 kV; source current, 80  µA; 
capillary temperature, 350°C; capillary voltage, 30.0 V; tube lens offset, −60 V; 
multipole 1 offset, -2.00 V; multipole 2 offset, -7.50 V; sheath gas flow (N2), 60 
Auxiliary Units; sweep gas flow (N2), 6 Auxiliary Units. Data were acquired both in 
full scan and product ion scan (MS2 and MS3) modes using mass scan range m/z 
100-1000. The collision energy was optimized at 32-37%. 
 
2.4 LC-UV stability indicating method 
2.4.1. LC-UV analyses 
A Shimadzu HPLC system, consisting in two LC-10AD Vp module pumps and a 
DGU-14-A on-line vacuum degasser, was used. The analyses were carried out on a 
Phenomenex (Torrance, CA, USA) Kinetex EVO C18 100 Å column (150 x 3 mm, 
5 µm dp) with a Phenomenex EVO C18 security guard column. The mobile phase 
(flow rate 0.6 mL min-1) was composed of eluent A, ammonium bicarbonate buffer 
(10 mM, pH 9.2), and eluent B, acetonitrile, while the initial ratio A:B was set at 
84:16 (v/v). The elution was done using the following gradient: from 0 to 8 min, the 
composition was increased from 16.0 to 22.0% B and then maintained 7 min. From 
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15 min, the percentage of eluent B was decreased in 1 min to 16.0%and then 
maintained 6 min for column equilibration. The eluents A and B were filtered 
through a 0.45 µm PVDF membrane filter prior the use. A SIL-10AD Vp 
autosampler was used for the injection of samples (5 µL). The SPD-M10A Vp 
photodiode array detector was used to detect TRX and the degradation products at 
254 nm. A LC solution 1.24 software was used to process the chromatograms. All 
the analyses were carried out at room temperature. 
 
2.4.2. Preparation of standard stock solutions for validation process 
The standard stock solution of purified triHer (200 µg mL-1) was prepared by 
dissolving an appropriate amount (about 40 mg) in 200 mL of water, whereas D1 
combined stock solution was prepared by dissolving about 7 mg of D1 in 50 mL of 
DMSO (final concentration 140 µg mL-1). To obtain the working solutions used in 
the validation protocol both triHer and DP stock solutions were properly diluted 
using water or a mixture of eluent A-eluent B-DMSO (50:10:40, v/v/v) respectively. 
 
2.4.3. Preparation of test solutions 
2.4.3.1. Test solution for triHer assay of TRX batches 
About 30 mg of TRX were accurately weighed and dissolved with water in a 50 mL 
volumetric flask. An aliquot of 2 mL of the solution was then diluted to 25 with 
water. The sample was analysed by LC-UV after filtration over 0.45 µm PVDF 
membrane filter. 
 
2.4.3.2. Test solution for degradation product assay of TRX batches 
About 60 mg of TRX were weighed and dissolved in 10 mL of a mixture of eluent 
A-eluent B-DMSO (50:10:40, v/v/v). The sample was analysed by LC-UV after 
filtration through 0.45 µm PVDF membrane filter. 
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2.4.3.3. Test solutions for triHer assay in TRX formulations 
Venolen® capsules: the content of 10 capsules was mixed and about 340 mg of the 
mixture were weighted and transferred into a 200 mL volumetric flask and filled up 
to volume with water. An aliquot of 3 mL of the resulting solution was then diluted 
to 100 mL in water. Fleboside® coated tablets: 10 coated tablets were finely grounded 
in a mortar and about 700 mg of the mixture were weighted and transferred into a 
500 mL volumetric flask. An aliquot of 50 mL of water were added and the mixture 
was sonicated for 5 min. Afterwards, the volumetric flask was filled up to volume 
with water. An aliquot of 3 mL of the solution was then diluted to 50 mL with water. 
Fleboside® ampoules: the content of 5 ampoules was accurately mixed and 3 mL of 
the resulting mixture were diluted to 100 mL with water. An aliquot of 3 mL of the 
solution was further diluted to 100 mL with water. Finally, the samples were 
analysed by LC-UV after filtration over 0.45 µm PVDF membrane filter. 
 
2.4.3.4. Test solutions for degradation product assay in TRX formulations 
Venolen® capsules: the contents of 10 capsules of the drug product Venolen® were 
mixed and about 340 mg of the mixture were weighted and transferred into a 50 mL 
volumetric flask. After addition of 20 mL of eluent A-eluent B-DMSO (50:10:40, 
v/v/v), the solution was stirred for 20 min and then filled up to volume. Fleboside® 
coated tablets: 10 coated tablets were finely grounded in a mortar and about 700 mg 
of the mixture were weighted and transferred into a 50 mL volumetric flask. The 
mixture was sonicated for 5 min with 20 mL of eluent A-eluent B-DMSO (50:10:40, 
v/v/v) and the volumetric flask was filled up to volume with the same solvent. 
Fleboside® ampules: the contents of 5 ampoules were accurately mixed and 3 mL of 
the resulting mixture were diluted to 25 mL with an eluent A-eluent B-DMSO 
(50:10:40, v/v/v) mixture. The samples were analysed by LC-UV after filtration over 
0.45 µm PVDF membrane filter. 
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2.4.3.5. Stability of stock solutions 
A 1 mg mL-1 stock solution of TRX, triHer and D1 were prepared in a solvent 
mixture constituted by eluent A-eluent B-DMSO (50:10:40, v/v/v). The stability of 
the stock solutions was assessed analysing the solutions immediately after their 
preparation, at the end of the study (3 weeks) and after two months of storage. The 
stock solutions were stored at 4°C and remained stable throughout the study. 
 
2.4.4. Validation procedure 
2.4.4.1. System suitability 
The system suitability parameters, resolution (Rs), area repeatability and asymmetry 
factor (As) were calculated as previously reported27. 
 
2.4.4.2. Selectivity 
To assess the method selectivity, a mixture of purified tetraHer, diHer and triHer was 
dissolved in 1 N HCl (t = 4 h, T = 50°C) and analysed by LC-UV. The 
chromatographic separation of tetraHer, diHer, triHer, D1, D2, D3 and other 
impurities, arising from the degradation in acidic condition, was evaluated after LC-
UV analysis by calculation of the resolution factors (Rs). Moreover, the selectivity 
was evaluated by preparing a combined placebo constituted by the excipients of the 
drug products: Venolen® capsules (ascorbic acid and titanium dioxide); Fleboside® 
coated tablets (titanium dioxide, gum arabic, corn starch, talc, PVP, colloidal silica, 
magnesium stearate, calcium carbonate, kaolin, orange yellow (E110), indigotine 
(E132), sucrose and the active ingredient carbazochrome) and Fleboside® ampoules 
(sodiumchloride and carbazochrome). For LC-UV analysis, the solutions were 
prepared following the same protocol of test solutions. 
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2.4.4.3. Robustness 
The robustness was determined by varying two parameters: the mobile phase pH and 
the percentage com-position of eluents. The influence of the mobile phase pH was 
determined at three different values of pH: 9.0, 9.2 and 9.4 being 9.2 the reference 
value by analysing the same mixture of the standards used for the selectivity. The 
influence of mobile phase composition was assessed by modifying the initial and 
final percentages of eluent B (±5% compared to the reference values). In all cases 
the effects of the changes applied to the method have been evaluated by calculating 
the resolution factors (Rs). 
 
2.4.4.4. LOD-LOQ 
The determination of LOD and LOQ was based on signal-to-noise ratio: this was 
evaluated by comparing measured signals from samples of triHer and D1 at low 
concentrations with those of blank samples and by establishing the minimum 
concentration at which analytes can be reliably detected (LOD; S/N = 3) or quantified 
(LOQ; S/N = 10). 
 
2.4.4.5. Linearity 
Linearity of the method was evaluated at five equispaced concentration levels by 
diluting the standard stock solutions to give solutions over the range 50–150% of 
label claim for triHer and 0.075-0.5% for D1. These were injected in triplicate and 
the peak areas were inputted into a Microsoft Excel® spread-sheet to plot calibration 
curves. To fulfil basic requirements such as homoscedasticity and linearity, the 
Bartlett test and the lack-of-fittest were respectively performed at 95% significance 
level. 
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2.4.4.6. Precision 
Precision was evaluated in terms of repeatability and intermediate precision. The 
repeatability was investigated using six separate solutions prepared by appropriate 
dilution of the stock solutions of triHer and D1 at 100% and 0.2% of label claim 
respectively. Each solution was injected in duplicate and the peak areas obtained 
were used to calculate means and RSD values. The intermediate precision was 
checked on three different days, by preparing and analysing in triplicate three 
solutions prepared as reported for the repeatability; the means and RSD values were 
calculated from peak areas. 
 
2.4.4.7. Accuracy 
To assess accuracy, freshly prepared placebo of the drug products was spiked with 
various amounts of triHer at 50 - 150% concentration levels and D1 at 0.075 - 0.5% 
concentration levels. Each solution was injected in triplicate and the peak areas were 
used to calculate means and RSD values and compared with those obtained with 
standard solutions. 
3. Results and discussion: 
3.1. MS and LC–MSn studies on TRX 
Mass spectrometry source conditions were optimized by flow injection analysis on 
TRX. Analyses were performed in positive ionization mode showing the presence of 
at least three principal ions at m/z 787, 743, 699 corresponding to the [M+H]+ of 
triHer (four isomers possible), diHer (six isomers possible) and tetraHer (one only 
isomer), respectively. No ions corresponding to the monoHer (four isomers possible) 
were detected. The MS2 experiments on each parent ion gave a fragment ion 
corresponding to the loss of the sugar moiety (308 u), while MS3 experiments gave 
the sub-sequent loss of the hydroxyethyl group (44 u) (Table 1). 
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Compound MW MS (m/z) MS2 (m/z) MS3 (m/z) 
diHer 698 699 [M+H]+ 391 [M+H-308]+ 347 [M+H-308-44]+ 
triHer 742 743 [M+H]+ 435 [M+H-308]+ 391 [M+H-308-44]+ 
tetraHer 786 787 [M+H]+ 479 [M+H-308]+ 435 [M+H-308-44]+ 
D1 434 435 [M+H]+ 391 [M+H-44]+ 347 [M+H-88]+ 
   373 [M+H-62]+  
D2 478 479 [M+H]+ 435 [M+H-44]+ 391 [M+H-88]+ 
   391 [M+H-88]+ 373 [M+H-62]+ 
D3 390 391 [M+H]+ 347 [M+H-44]+ 303 [M+H-88]+ 
 
Table 1. Mass data of principal Hers in TRX and DPs (D1, D2 and D3) 
 
This first result confirmed that TRX is a mixture of different compounds. 
Chromatographic conditions for LC-MSn analyses were setup to obtain the best 
separation of the Hers and, after degradation, the potential, more lipophilic, DPs. The 
presence of a polar sugar moiety in Hers but not in the corresponding DPs, combined 
with the variable number of hydroxyethyl groups, made the chromatographic 
separation of the analytes a challenging task. In first instance we investigated the role 
of the aqueous mobile phase pH, by testing various acidic and alkaline buffers on 
different stationary phases featured by lipophilic (Phenomenex Luna C18(2)) or 
aromatic/polar (Phenomenex Sinergy Polar) interactions respectively. In all cases 
when the mobile phase was acidified, the elution order of Hers was tetraHer, triHer 
and diHer, even if the peaks of triHer and diHer co-eluted (data not shown); 
conversely, the use of an alkaline mobile phase gave good results in terms of 
separation of Hers. Accordingly, the stationary phase which gave the best results was 
the Phenomenex Gemini NX C18, stable in a wide pH range (from 2 to 13), 
maintained at 25°C. The mobile phase (flow rate 0.2 mL min-1) was composed of 
eluent A: ammonium bicarbonate buffer (10 mM, pH 9.2) and eluent B: CH3CN 
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using a gradient elution. In the chromatogram depicted in Figure 1, the peaks at 
retention time of 3.03, 4.76 and 5.74 min correspond to tetraHer, diHer and triHer, 
respectively. The different elution order in acidic conditions respect to alkaline 
conditions could be attributed to the presence of different steric interactions of the 
three Hers with the stationary phase used due to the ionization grade at different pH, 
the number of free hydroxyl groups of the single Hers and the presence of the sugar 
moiety. The LC-MS analysis confirmed the molecular weight of the three principal 
Hers: indeed the ions at m/z 787, 699 and 743 correspond to the protonated molecules 
[M+H]+ of tetraHer, diHerand triHer, respectively. With the mentioned 
chromatographic separation, the analysis in mass range of the three ions gave rise 
only to one predominant peak, stating that only one principal isomer could be 
considered for each one. 
 
 
Figure 1. a) LC–MS chromatogram of TRX; b) ESI+ full MS of triHer; c) ESI+ full MS of diHer; d) ESI+ full MS of 
tetraHer 
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3.2. LC–MS data on TRX forced degradation 
In order to characterize the intrinsic chemical stability of TRX, a forced degradation 
study was performed following the requirements of ICH guidelines [28]. 
Furthermore, to avoid unrealistic degradation pathways, the stress conditions were 
optimized to obtain a 10 - 15% degradation of the parent compound. In acidic 
conditions (1 N HCl, 50°C), the formation of three peaks eluting at 11.71, 16.13 and 
17.86 min respectively was evident after 4 h (Figure 2). Their positive ESI-MS 
spectra gave rise to the base peaks at m/z 479, 435 and 391, corresponding to the loss 
of rutinose moiety (308 u with respect to tetraHer, triHer and diHer, respectively), 
attributable to the Hers aglycones (D2, D1 and D3, respectively). The structure was 
confirmed also from the MS2 and MS3 analyses (Supplemental 1). As expected, for 
prolonged exposure to the acidic conditions, the intensity of D2, D1 and D3 increased 
while the intensity of triHer, diHer, tetraHer decreased (data not shown). Moreover, 
the exposure of TRX to 1 N HCl at room temperature did not cause the cleavage of 
the O-β-glycosidic bond of Hers, implying that the temperature is a key parameter 
for its stability. In alkaline, oxidative conditions and in the presence of both UV light 
and sunlight TRX did not undergo degradation (Table 2). The degradation in acidic 
conditions was also repeated on the pure Hers obtained by column chromatography 
and not commercially available as standard. As a result, it was demonstrated that D1 
is the direct degradation product of triHer, D2 of tetraHer and D3 of diHer. Overall, 
these data allowed to propose the degradation scheme of TRX reported in Figure 3, 
in which D1 can be also defined the stability indicator of the mixture. 
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Figure 2. a) LC–MS chromatogram of TRX degradation in 1 N HCl, 50◦C and 4 h; b) ESI+ full MS of D1; c) ESI+ full MS 
of D2; d) ESI+ full MS of D3 
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Table 2. Results of the forced degradation studies of TRX and purified Hers 
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Figure 3. Degradation pathway of TRX 
 
3.3. Purification of Hers, synthesis of DPs and their structural characterization 
Since pure Hers are not commercially available, the only possibility was to obtain 
them from TRX chromatographic separation. Even though this is a challenging task, 
the availability of pure Hers may lead to significant novelty, improving both the 
analytical characterization of TRX and the pharmacological knowledge of its 
components. The purification of TRX resulted very complex and time-consuming 
but the use of flash silica gel and a gradient elution with a mixture of ethyl acetate-
isopropanol-water-acetic acid gave rise to obtain the three products present in the 
mixture at a good purity. The NMR spectra of triHer were in perfect agreement with 
the previous reported in literature25 and the 13C NMR chemical shift of tetraHer were 
all consistent with that of triHer except for the C5 upfield from 156.64 to 153.40 
ppm, caused by the presence of the hydroxyethyl group in this position. The low 
concentration and the coelution with triHer (as predictable in acid elution) were the 
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major problems encountered in the separation of diHer from the mixture. As a 
consequence, HPLC-UV purity of diHer resulted, for these reasons, of 63% but the 
only impurity present was triHer, confirmed also from the NMR spectra. The 
analysis of diHer 13C NMR spectrum evidenced C4’ and C3’ chemical shifts of 
150.53 and 147.69 ppm respectively (consistent with the presence of the 
hydroxyethyl substitution) and the downfield of the C7 (165.19 ppm) attributable to 
the free phenolic group. All these data prompted to confirm the isolation and the 
characterization of three single isomers: diHer (3’,4’,-Di-O-(β-hydroxyethyl)rutin), 
triHer (3’,4’,7-Tri-O-(β-hydroxyethyl)rutin) and tetraHer (3’,4’,5,7-Tetra-O-(β-
hydroxyethyl)rutin) (Supplemental 2 and 3). The synthesis of DPs was performed 
both to confirm their structures and to allow the development and validation of the 
stability indicating LC-UV method. The preparation of D1, D2 and D3, starting from 
purified Hers, was performed based on the forced degradation data; indeed, the 
synthetic protocol was optimized by adjusting the hydrochloric acid concentration 
and the time of reaction to obtain the desired products in good yield and high purity. 
For D2 and D3 the purification through a silica column chromatography was also 
required. Furthermore, the poor solubility of DPs in the common solvents was 
overcome solubilizing them in basic medium (e.g. ammonium bicarbonate buffer) 
with an aliquot of DMSO. Similarly, DPs were dissolved in pyridine-d5 to carry out 
1H NMR and 13C NMR analyses. The NMR analyses of the DPs confirmed the 
position of hydroxyethyl substituents. The upfield of the C5 of D2 (160.43 ppm) in 
respect to the same position of D1 and D3 (161.74 and 162.01 ppm respectively) and 
the downfield of the C7 of D3 (165.73 ppm) in respect to the same position of D1 
and D2 (165.18 and 163.81 ppm respectively), prompted to confirm the synthesis 
and the characterization of three single isomers: D3 (3’,4’-Di-O-(β-
hydroxyethyl)quercetin), D1 (3’,4’,7-Tri-O-(β-hydroxyethyl)quercetin) and D2 
(3’,4’,5,7-Tetra-O-(β-hydroxyethyl)quercetin) as reported in Figure 4,5 and 6. 
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Figure 4. 1HNMR of purified Hers and synthesized DPs (D1, D2 and D3) 
 
H diHer triHer tetraHer D3 D1 D2
6  6.36 (s; 1H) 6.36 (s; 1H) 6.54 (s; 1H) 6.62 (s; 1H)  6.63 (s; 1H) 6.67 (s; 1H)
8   6.71 (s; 1H) 6.72 (s; 1H) 6.80 (s; 1H) 6.70 (s; 1H) 6.78 (s; 1H) 6.90 (s; 1H) 
2’  7.84 (s; 1H) 7.84 (s; 1H) 7.83 (s; 1H) 8.41 (s; 1H)    8.40 (s; 1H) 8.37 (s; 1H)
5’  7.10 (d; 1H; J=8.7Hz) 7.13 (d; 1H; J=7.05Hz) 7.10 (d; 1H; J=8.58Hz) 7.31(d;J=9Hz) 7.29 (d;1H; J=8.55Hz) 7.28 (d; 1H; J=8.88Hz)
6’ 7.70 (d; 1H; J=8.1Hz) 7.70 (d; 1H; J=8.50Hz) 7.71(d; 1H; J=8.58Hz) 8.12 (d; 1H; J=8.25Hz) 8.22 (d;1H; J=8.58Hz) 8.17 (d; 1H; J=8.25Hz)
1’’ 5.39 (d; 1H; J=5.7Hz) 5.42 (d; 1H; J=5.82Hz) 5.26 (d; 1H; J=7.05Hz) - - -
6''' 1.02 (d; 3H; J=3.3Hz) 0.96 (d; 3H; J=4.59Hz) 0.98 (d; 3H; J=6.12Hz) - - -
H sugar 3.05-3.75 (m; 10H) 3.06-3.75 (m; 10H) 3.05-3.76 (m; 10H) - - -
H-A 3.95-4.1 (m; 4H) 4.06-4.11 (m; 6H) 4.06-4.14 (m; 8H) 4.33-4.41 (m; 4H) 4.01-4.08 (m; 6H) 4.18--4.36 (m; 8H)
H-B 3.17-3.37 (m; 4H) 3.23-3.75 (m; 6H) 3.22-3.78 (m; 8H) 4.13-4.19 (m; 4H) 3.76-4.01 (m; 6H) 4.44-4.60 (m; 8H)
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Figure 5. 13CNMR of purified Hers and synthesized DPs (D1, D2 and D3) 
 
 
 
Carbon DiHer TriHER TetraHER  D3 D1 D2
2 157.23
b1
156.56
a1 158.23 148.0 151.3 150.83
3 133.71 133.73 135.97 136.5 138.55 136.75
4 173.43 173.07 172.50 176.1 177.32 171.1
5 157.03
b1
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a1 153.40 162.01 161.74 160.43
6 99.02 98.48 98.06 98.1 98.43 98.88
7 165.19 164.72 163.27 165.73 165.18 163.81
8 93.01 92.91 93.92 92.90 92.60 94.15
9 160.69 160.94 159.78 158.50 156.93 158.73
10 106.0 105.16 108.47 106.50 105.22 108.09
1’ 123.18 122.42 122.61 122.14 124.96 124.15
2’ 112.90 112.73 112.72 112.86 113.67 113.79
3’ 147.69 147.53 147.49 143.25 143.59 143.16
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4.3.4. LC-UV method development 
In the relevant literature a stability indicating HPLC method for TRX analysis is not 
reported. In fact, all the methods previously mentioned20-23,26 were used for the 
determination of TRX as triHer. Based on the LC-MS method conditions used in the 
investigation of the chemical stability of TRX, a LC-UV method was developed and 
validated. In order to achieve the separation of all the degradation products, a Kinetex 
EVO C18 stationary phase was used enhancing the peak shape of Hers and DPs 
(Figure 6a). Finally, the mobile phase composition was fine-tuned in order to obtain 
the required separation of all the analytes. Moreover, the analysis of a sample of TRX 
degraded in acidic conditions revealed the presence of D1 as the only DP. This 
confirmed that D1 can be considered the indicator of stability of TRX in stability 
studies (Figure 6b). The results obtained and the availability of the purified standards 
of triHer and D1 (Figure 7) suggested that the present LC-UV method can be used 
for the quantification of triHer and D1 in TRX drug substance and drug products. 
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Figure 6. a) LC-UV chromatogram of tetraHer, diHer and triHer standards in acidic solution (1 N HCl, t = 4 h, 50°C). b) LC-
UV chromatogram of TRX in the presence of 1 N HCl (4 h, 50°C) 
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Figure 7. a) LC-UV chromatogram of purified standard triHer (conc. 0.25 mg/mL). b) LC-UV chromatogram of synthetic 
standard D1 (conc. 0.25 mg/mL) 
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3.5. Method validation 
The method was validated following the ICH guidelines29. 
 
3.5.1. Selectivity  
The chromatogram reported in Fig. 4.a showed no peak interfering with analytes; the 
adjacent chromatographic peaks tetraHer/diHer, diHer/triHer, triHer/D2, D2/D1 and 
D1/D3 were separated with resolution factors greater than 2 suggesting that the 
impurities arising from degradation did not affect the selectivity of the method. For 
the whole validation procedure, triHer and D1 were considered; however, the 
selectivity of the method was evaluated by using all the analytes. To overcome the 
limited availability of D2 and D3 synthetic standards, the formation of DPs was 
obtained in situ from purified Hers at equal concentration, in the presence of HCl. 
Nevertheless, the attribution of the chromatographic peaks was confirmed by the 
injection of the corresponding synthetic standard. The chromatograms of the placebo 
solutions obtained by using the mixture of excipient used for Venolen® capsule, 
Fleboside® tablets and Fleboside® ampoules are reported in Figure 8. In the case of 
Fleboside® medicinal product the API carbazochrome, present in combination with 
TRX, was included in the excipient blend excluding its interference with analytes. 
Overall, these data highlighted the selectivity of the method. 
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Figure 8. LC-UV chromatograms of the placebo solutions obtained by using the mixture of excipient used for a) Venolen® 
capsule, b) Fleboside® tablets and c) Fleboside® ampoules 
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3.5.2. System suitability 
The suitability of the chromatographic system was demonstrated by comparing the 
obtained values, reported in Table 3, with the acceptance criteria of the CDER 
guidance document30. 
 
Table 3. System Suitability parameters 
 
3.5.3. Robustness 
As for selectivity, the robustness of the method was evaluated by using all the 
analytes. The role of the most critical parameters (pH and mobile phase composition) 
has been studied by introducing small but deliberate variations. As reported (Table 
4), the resolution values were always greater than 2.0 also in the case of some 
potential critical pair of adjacent peaks (e.g. D1/D3). 
  
Analyte 
Retention 
time (Rt, 
min) 
Relative 
Retention time 
(RRt, min) 
Repeatability 
of peak areaa 
Asymmetry 
factor 
Resolution 
factors 
tetraHer 3.652 0.53 0.87 1 
4.4 
(tetraHer/diHer) 
diHer 5.123 0.75 0.72 1.2 
3.7 
(diHer/triHer) 
triHer 6.845 1 0.76 1.5 8.2 (triHer/D2) 
D2 10.542 1.54 1.84 2 3.7 (D2/D1) 
D1 11.891 1.74 1.24 2 2.2 (D1/D3) 
D3 12.975 1.90 2.02 1.7  
aRSD values for six replicates 
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Factor Δ Rs tetraHer/diHer Rs diHer/triHer Rs triHer/D2 Rs D2/D1 Rs D1/D3 
Methoda  4.38 3.74 8.16 3.68 2.16 
pH 
9.0 3.49 2.76 8.73 4.15 2.02 
9.4 6.42 4.22 2.47 2.00 2.00 
% eluant B 
-5% 4.20 6.90 7.49 2.00 2.20 
+5% 4.22 3.13 7.96 2.91 2.22 
a the nominal values of the method were reported in the experimental part 
Table 4. Resolution values 
 
3.5.4. LOD-LOQ 
LOD and LOQ were determined at 254 nm, by analysing progressively low 
concentration solution of triHer and D1. LOD values for triHer and D1 were 0.4 µg 
mL-1 and 2.5 µg mL-1 respectively while LOQ values for triHer and D1 were 2.5 µg 
mL-1 and 4.0 µg mL-1 respectively. 
 
3.5.5. Linearity 
Five concentration levels within the range 50 - 150% of label claim of triHer were 
considered to study the linearity. For D1 at 0.2% level of concentration, a range value 
of 0.075-0.5% was used. Since the Bartlett test evidenced no significant difference 
(p > 0.05) among the variance values of replicates at different con-centration levels 
the best fit was obtained using an unweighted linear regression model. The linearity 
was observed in the expected concentration ranges, demonstrating their suitability 
for analysis. The results of the regression statistics for the analytes were reported in 
Table 5. The square of the correlation coefficient (r2 > 0.999) demonstrated a 
significant correlation between the concentration of analytes and the detector 
response; however, it was neither a proof of linearity, nor a useful measure of the 
calibration variability. Hence the lack-of-fit-test were performed on these data; the 
significance values (p > 0.05) obtained for all analytes indicated that a linear 
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regression model provides a good interpolation of the experimental data. Moreover, 
the evaluation of residual plot confirmed that underlying assumption like 
homoscedasticity was met as well as the goodness of fit of the regression model. 
Finally, the confidence interval of the y-intercepts includes zero; moreover, the 
relative residual standard deviations, expressed as percentage, were calculated and 
used to assess the precision of the regression: all values were < 1% except for those 
corresponding to D1 and triHer for degradation product (1.9 and 1.9%, respectively). 
 
 triHer D1 
Range (µg mL-1) 20 - 60 
5.1-35 
 
Slope (a) 10783.9 14360.3 
Standard error (SE) (a) 4387.6 4607.1 
Intercept (b) -5665.5 -1437.3 
(b) C.I.a -13007.7 ‒ 1676.7 -6097.9 ‒ 3223.3 
F 18122.7 p<0.01 17165.6 p<0.01 
R2 0.9993 0.9992 
RRSDb 1.0 1.9 
a 95% confidence interval 
bRelative residual standard deviation 
Table 5. Five levels calibration graphs for triHer and D1: unweighted regressions y = ax + b; three replicates for each level (n 
= 15) 
3.5.6. Precision 
The results obtained for the intra-day and inter-day are shown in Table 6. In all 
instances, RSD values were less than 2%, confirming the precision of the method. 
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Analyte Level % 
Intraday variation 
(n=12 RSD%) 
Interday variation (n= 9 
RSD%) 
triHer 100 1.5 1.4 
D1 0.2 1.2 1.1 
 
Table 6. Intraday and interday precision values for triHer and D1 
3.5.7. Accuracy 
Accuracy has been determined by application of the analytical procedure to recovery 
studies, where known amount of standards was spiked into the placebo. The results 
of accuracy studies were shown in Table 7. The average recovery values were 98.8 
and 97.9 for triHer and D1 respectively demonstrating that the method was accurate 
within the desired range of concentrations. 
 
Level % triHer Level % D1 
50 98.1 0.075 97.6 
75 99.0 0.1 97.4 
100a 99.2 0.2b 99.4 
125 98.2 0.3 97.2 
150 99.7 0.5 98.1 
Mean 98.8 Mean 97.9 
SD 0.68 SD 0.88 
RSD 0.7 RSD 0.9 
a 100% of label claim is equivalent to 40 µg mL-1 of triHer 
b 0.2% of label claim is equivalent to 14 µg mL-1 of D1  
 
Table 7. Accuracy: Recovery data for triHer and D1. 
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3.6. Analysis of TRX in drug substances and drug products 
The LC-UV method was applied for the quantification of triHer and D1 in the API 
batches and in commercial drug products of TRX. LC-UV chromatograms of test 
solutions for triHer assay were reported in Figure 9 and 10. The LC-UV method 
allowed the quantification of the triHer due to the availability of a pure standard of 
triHer obtained by the procedure of purification described (concentration ranged 
between 40.82 µg mL-1 and 51.33 µg mL-1). In the test solutions of degradation 
product assay in TRX formulations (Figure 11 and 12) the formation of D1 was 
observed only in Fleboside® ampoules where it was quantified in 4 µg mL-1 
corresponding to 0.06% level. The attribution of D1 as stability-indicator is 
confirmed by the superimposition of LC-UV chromatograms of Fleboside® 
ampoules and TRX API batch (Figure 13). 
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Figure 9. LC-UV chromatograms of test solution for triHer assay in a) TRX batch n° 335539190, b) TRX batch n° 
33553C024 and c) TRX batch n°33553T164 
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Figure 10. LC-UV chromatograms of test solution for triHer assay in a) Fleboside® coated tablets, b) Venolen® capsules and 
c) Fleboside® ampoules 
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 min
0
5
10
15
20
25
30
35
40
mAU
254nm,4nm (1.00)
tetraHer
diHer
triHer
51.33 µg/ml
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 min
0
5
10
15
20
25
30
35
40
mAU
254nm,4nm (1.00)
tetraHer
diHer
triHer
45.81 µg/ml
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 min
0
5
10
15
20
25
30
35
40
mAU
254nm,4nm (1.00)
tetraHer
diHer
triHer
40.82 µg/ml
a
b
c
Chapter 3 
85 
 
 
Figure 11. LC-UV chromatograms of test solution degradation product assay in a) TRX batch n° 335539190, b) TRX batch 
n° 33553C024 and c) TRX batch n°33553T164 
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Figure 12. LC-UV chromatograms of test solution degradation product assay in a) Fleboside® coated tablets, b) Venolen® 
capsules and c) Fleboside® ampoules   
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Figure 13. LC-UV chromatograms of test solution degradation product assay in Fleboside® ampoules overimposed to TRX 
batch n° 335539190 
 
4. Conclusion: 
In this work, it was proposed for the first time the degradation pathway of TRX 
mixture based on a complete forced degradation study performed by LC-MS, 
following the ICH guidelines. The isolation and the characterization of three 
predominant components of TRX and the synthesis and characterization of all the 
DPs allowed the development and the validation of a sensitive and robust LC-UV 
stability indicating method. The method was also successfully applied for the 
quantification of triHer and D1, in both drug substances and drug products. 
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Graphical Abstract: 
 
Abstract: 
Adenosine 5’-tetraphosphate (Ap4) is a ubiquitous metabolite involved in cell 
signaling in mammals. Its full physiological significance remains unknown. Here we 
show that two enzymes committed to NAD biosynthesis, nicotinamide 
phosphoribosyltransferase (NAMPT) and nicotinate phosphoribosyltransferase 
(NAPT), can both catalyze the synthesis and degradation of Ap4 through their 
facultative ATPase activity. We propose a mechanism for this unforeseen additional 
reaction, and demonstrate its evolutionary conservation in bacterial orthologs of 
mammalian NAMPT and NAPT. Furthermore, evolutionary distant forms of 
NAMPT were inhibited in vitro by the FK866 drug but, remarkably, it does not block 
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synthesis of Ap4. In fact, FK866-treated murine cells showed decreased NAD but 
increased Ap4 levels. Finally, murine cells and plasma with engineered or naturally 
fluctuating NAMPT levels showed matching Ap4 fluctuations. These results suggest 
a role of Ap4 in the actions of NAMPT, and prompt to evaluate the role of Ap4 
production in the actions of NAMPT inhibitors. 
1. Introduction: 
Nicotinamide phosphoribosyltransferase (NAMPT) and nicotinate 
phosphoribosyltransferase (NAPT) are structurally similar NAD biosynthetic 
enzymes belonging to the class of dimeric type II phosphoribosyltransferases 
(PRTases)1. They bind nicotinamide (Nam) or nicotinic acid (Na) as the respective 
substrate, catalyzing their reversible transfer to the ribose 5-phosphate moiety of the 
phosphoribosyl pyrophosphate (PRPP), with production of nicotinamide 
mononucleotide (NMN) or nicotinate mononucleotide (NaMN) and pyrophosphate 
(PPi). Both classical niacin vitamins, Nam and Na, are physiologically 
physiologically relevant precursors for NAD; Nam is used in the amidated salvage 
route, whereas Na is used in the deamidated route, also known as the Preiss-Handler 
pathway2. The two metabolic routes contribute to the overall NAD pool in mammals 
with different efficiency and in different combinations depending on the tissue3, cell 
type4, and metabolic status5. In such metabolic context, NAMPT and NAPT are also 
recognized as rate-limiting6,7 and thus considered as key druggable targets8,9. Besides 
the PRTase reaction above, these two enzymes are known to catalyze a facultative 
ATP hydrolysis (ATPase). Most studies on this subject have been carried out on 
human NAMPT10,11, Salmonella typhimurium NAPT12-16, and human NAPT17. Such 
ATPase activity is intriguing since it couples weakly, i.e., not stoichiometrically, to 
the PRTase and involves the formation of a phosphor-His intermediate at the active 
site (phosphorylated H247 in human/ murine NAMPT, H219 in S. typhimurium 
NAPT, and H213 in human NAPT). Therefore, NAMPT and NAPT are uniquely 
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ATPsensitive enzymes that have mechanistically evolved to regulate their own 
NMN/NaMN synthesis by linkage to an ATP-dependent autophosphorylation 
process. This link, however, is not mandatory and both enzymes readily synthesize 
pyridine mononucleotides even in the absence of ATP, albeit with decreased 
catalytic efficiency11,16. At physiological Mg2+-ATP concentrations, NAMPT and 
NAPT are probably phosphorylated, providing efficient capturing of the pyridine 
substrate and conversion to the corresponding product. Thus, their ATPase activity 
is seen as an in vivo thermodynamic drive toward NMN/NaMN synthesis and, in this 
view, intracellular ATP is the fuel that, via these enzymes, allows recycling to NAD 
of the two niacin moieties even at very low intracellular concentration11,13 
The complexity is further increased by the functional pleiotropism of NAMPT within 
mammalian organisms. Besides regulating intracellular NAD homeostasis7, NAMPT 
is subject to a circadian transcriptional control by the CLOCK machinery18, it 
belongs to systemic regulatory networks19,20, and it is a serum-circulating secreted 
protein known as PBEF21 or visfatin22, which has an additional property as an 
immunomodulating cytokine23-25. Recently, the TLR4 receptor in human lung, which 
mediates the innate immunity response, has been identified as the receptor of 
circulating NAMPT26, but controversies remain regarding the secretion mechanism 
of the enzyme, the involvement of NAMPT catalytic activity in the cytokine 
function27, and the bioavailability of enzyme reactants in extracellular fluids6. As to 
NAPT, no extracellular function has been yet ascribed to this protein, but its presence 
in human sera as a circulating active enzyme has been recently reported4. 
This work started from the serendipitous finding of an unpredicted reaction product 
formed in vitro by NAMPT and NAPT from the ATP substrate. We identified this 
product as adenosine 5’-tetraphosphate (Ap4) and proved it to be enzymatically 
formed by a phosphor-transfer reaction to ATP, i.e., an unforeseen additional 
reaction catalyzed by such type II PRTases. Ap4 is known as the most potent 
vasoactive purinergic mediator in mammals, circulating in plasma at nanomolar 
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concentrations, and exerting vasoconstriction through activation of the P2X1 
receptor28. Thus, the ability to synthesize Ap4 could be important for the 
extracellular signaling roles of these enzymes. Moreover, as Ap4 has long been 
known in mammals as an intracellular molecule of unclear metabolic origin29, our 
data identify two of the enzymes likely to contribute to its homeostasis. 
2. Results:   
2.1 Ap4 Is an Authentic ATP-Derived Product of the NAMPT-Catalyzed Reaction 
Initial C18-HPLC assays aiming to evaluate ATP usage by murine NAMPT showed 
the time-dependent formation of an unpredicted product in the reaction mixture, 
distinct from ADP (Figure 1A). Its UV spectrum was typical of an adenylate 
compound, i.e., superimposable to that of both ATP and ADP (Figure 1B). The 
unknown product was absent in control mixtures including heat-inactivated enzyme, 
or missing individual mixture components ATP and Mg2+ ions (not shown). 
Furthermore, the H247E mutant30, which is ATP insensitive despite its retained 
NMN synthesis capability (Table 1), did not form any of this product (Figure 1C). 
This ruled out any non-enzymatic origin and suggested that it was a novel ATP-
derived product of NAMPT. The novel product was purified by TSK-DEAE 
chromatography for further characterization (Figure 1D). The purified species was 
lyophilized to remove the volatiles and resuspended in suitable solutions at 
concentrations that were calculated spectrophotometrically based on the adenosine 
content (see Methods section). The solubilized species was found to be stable 
through several freezing/thawing cycles, and was next subjected to chemical, 
enzymatic, and liquid chromatography-electrospray ionization mass spectrometry 
(LC-ESI-MS) analyses. We identified a phosphate/adenosine stoichiometry of 4:1 
(Figure 2A), a progressive digestion by alkaline phosphatase to ATP, ADP, AMP, 
and adenosine in this order (Figure 2B), digestion by phosphodiesterase to AMP and 
then to adenosine (Figure 2C), and a mass spectrum under the X peak of m/z 586 
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[M-H]- (Figure 2D). Orthogonal analysis of these results identified the purified 
NAMPT product as Ap4. Parallel enzyme digestion tests of a pure Ap4 standard 
yielded results identical to those obtained with the purified NAMPT product. 
Moreover, the NAMPT product and the Ap4 standard co-eluted after 
chromatography in two distinct separations, i.e., ion-pair reverse phase (Figure 2E) 
and anion exchange (Figure 2F). Taken together, this evidence indicates the novel 
NAMPT product is indeed an authentic Ap4. 
 
 
Figure 1. Identification of Ap4 as a New Enzymatic Product A. Analytical C18-HPLC UV profiles from a typical ATPase 
activity assay (‘‘S’’) of murine NAMPT wild-type ( ̴ 15 mM) incubated in the presence of 2.4 mM ATP. The horizontal axis 
shows only the region that visualizes the result. ‘‘X’’ indicates the newly identified reaction product. The ‘‘control’’ refers to 
a parallel blank mixture without the enzyme showing no hydrolysis of ATP and its negligible contamination by ADP. B. UV 
spectra of the peaks in (A), at comparable maxima corresponding to 1 absorbance unit. C. Analytical C18-HPLC UV profiles 
from a reaction assay carried out as in (A) but using the murine NAMPT mutant H247E (   ̴40 mM). D. Preparative HPLC 
purification by TSK-DEAE chromatography of the enzymatically formed species X (the fractions collected are within the curly 
bracket) 
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Enzyme 
species 
treatment 
PRTase rates (mU/mg)a ATPase rates (mU/mg)b 
NMN 
synthesis 
NaMN 
synthesis 
ATP 
consumption 
ADP 
synthesis 
Pi 
synthesis 
Ap4 
synthesis 
murine 
NAMPT 
wild type 
None 31.1 (4.77) 5.86 (0.59) 8.54 (1.02) 5.82 (1.08) 3.19 (1.40) 2.66 (0.47) 
+FK866 Nd Nd 10.4 (0.12) 9.58 (0.83) 9.02 (1.64) 1.51 (0.27) 
murine 
NAMPT 
H247E 
None 3.21 (0.20) Nd Nd ≤0.02 ≤0.02 Nd 
+FK866 Nd Nd Nd ≤0.02 ≤0.03 Nd 
human 
NAPT wild 
type 
None Nd 16.0 (1.15) 1.48 (0.08) 1.17 (0.10) 1.14 (0.21) 0.16 (0.04) 
+FK866 Nd 15.5 (0.88) 1.57 (0.07) 1.25 (0.04) 1.31 (0.03) 0.19 (0.03) 
human 
NAPT 
H213A 
None Nd 76.4 (11.2) ≤0.10 ≤0.10 ≤0.10 Nd 
+FK866 Nd 81.1 (3.82) ≤0.10 ≤0.10 ≤0.10 Nd 
Acinetobac
ter NadV 
wild type 
None 30.6 (1.84) Nd 1.14 (0.09) 1.01 (0.08) 0.89 (0.08) 0.12 (0.02) 
+FK866 8.04 (2.06) Nd 23.4 (2.96) 14.9 (1.22) 6.17 (1.65) 8.54 (2.06) 
Staphyloco
ccus PncB 
wild type 
None Nd 441 (56.7) 13.0 (0.39) 8.54 (0.25) 4.06 (0.11) 4.48 (0.14) 
+FK866 Nd 424 (47.0) 14.3 (0.59) 9.38 (0.37) 4.44 (0.16) 4.94 (0.21) 
 
Table 1. PRTase and ATPase Activities by Orthologous NAMPT and NAPT Enzymes 
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Figure 2. Structural Assessment of the Enzyme-Formed Ap4 Product A. Molar ratio in the purified species X between the 
organic phosphate released after chemical digestion and quantified by malachite green, and the adenosine content quantified 
by UV absorption (arrows). A reference curve was created from the indicated standards, all with known Pi/adenosine 
stoichiometry. B. Time course digestion of the purified species X by calf intestine alkaline phosphatase (see also Figure S1A). 
C. Time course digestion of the purified species X by snake venom phosphodiesterase I (including a contaminating 50-
nucleotidase that causes AMP-toadenosine conversion, see also Figure S1B). D. LC-ESI-MS analysis of the purified species 
X. E. Analytical C18-HPLC UV profiles of the purified species X and an Ap4 standard (both   ̴0.8 nmol). Dotted line, the 
methanol gradient applied for elution. F. Analytical TSK-DEAE-HPLC UV profiles of the purified species X and an Ap4 
standard (both 0.8 nmol average). Dotted line, the salt gradient applied for elution 
 
2.2 Investigation of Ap4 formation and its modulation [31] 
Co-authors deeply studied the following aspects related to Ap4 synthesis and its 
modulation: 
-Mechanism of enzymatic formation of Ap4. 
-ATP hydrolysis and Phosphor Transfer by Evolutionary Distant Type II PRTases. 
-In vitro Modulation of Murine NAMPT ATPase versus PRTase Activities. 
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2.3 LC-MSn bioanalytical method for the quantification of Ap4 and other five 
analytes related to NAMPT activity in murine cells and Plasma 
With the aim to quantity Ap4 and ATP, ADP, Nam, NMN and NAD, a new LC-MSn 
bioanalytical quantitative method has been developed. MS source conditions were 
set up by flow injection analysis on analytes standards. Analyses were performed in 
both positive and negative ionization mode, according to the chemical features of 
each compound. Mass/Mass spectra are reported in Figure 3A. To perform a 
quantitative method, all the analytes of interest were monitored in Single Reaction 
Monitoring Mode (SRM) or Multiple Reaction Monitoring Mode (MRM) or in 
Mass/Mass Mode (MS2) (Figure 3B). Under a chromatographic point of view, The 
stationary phase was constituted by a Phenomenex Luna HILIC (150 x 2 mm, 3 µm) 
protected with a security guard (Luna HILIC, 4 x 2 mm) maintained at 25°C. While, 
the mobile phase was composed of eluent A: ammonium acetate buffer (100 mM, 
pH 5.8) and eluent B: CH3CN using an isocratic elution (30:70; A:B; v:v). The flow 
rate was set at 200 µl min-1 for 20 min, with an injection volume of 5 µl (Figure 3C). 
The LC-MSn bioanalytical method was assessed for the following parameters: % 
Recovery, % matrix effect, LOD (Lower Limit of Detection) and LOQ (Lower Limit 
of Quantification) and linearity (Figure 4). 
The sample preparation was performed with a protein precipitation approach with 
organic solvents as described in the experimental section. 
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Figure 3. A. MS/MS spectra of Ap4, ATP, ADP, Nam, MNM and NAD collected with flow injection analysis with a flow rate 
of 5 µl min-1. B. LC-MS analysis of standard compounds. C. MS parameters developed for the compounds detection 
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Figure 4. A. Recovery was evaluated by comparing the response ratio of the analyte physiologically present in the biological 
sample with the response ratio after adding the analyte before the PP and the evaporation treatment. B. The matrix effect was 
evaluated for each compound by comparing the response ratio in presence of matrix with the response ratio in the absence of 
it. C. LOD and LOQ. D. Linearity was performed using the external calibration method and it was calculated as unweighted 
linear regression y = ax + b 
 
2.4 In Vivo Regulation of Ap4 Levels by NAMPT in Murine Cells and Plasma 
We proceeded to evaluate Ap4 levels in mammalian cells and their dependence on 
NAMPT in vivo. For this we used an in-house B16 melanoma cell line previously 
shown to be enriched in NAMPT32. We had previously engineered33 an 
overexpressing cell line (B16 FLAG-NAMPT) expressing ca. 160% of wild-type 
NAMPT levels, and a silenced cell line (B16 shNAMPT Low) expressing less than 
20% of wild-type NAMPT (see Figure 5 for expression levels). The levels of the 
nucleotides of interest determined by LC-ESI-MS in these cells are reported in Table 
2. The overall data show a low ATP/ADP ratio that has also been observed by 
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others34 in the same cell type (B16), as well as higher than expected Nam levels, 
which can be explained by the presence of high micromolar concentrations of Nam 
in the commercially available medium in which cells were grown (32.7 mM, as 
depicted in the product datasheet). It is unlikely that the low ATP/ADP ratio, as well 
as the high Nam/NAD ratio, are instead given by degradation during sample 
preparation, as standards were processed in parallel with no sign of degradation. As 
expected, NMN and NAD levels correlated with NAMPT expression. More 
surprisingly, the Nam levels were lower in shNAMPT compared with wild-type 
NAMPT. Notably, we could measure intracellular Ap4 levels at 0.527 ± 0.068 
nmol/mg. Such levels were increased in cells overexpressing NAMPT and reduced 
in cells silenced for the enzyme. We also observed an almost doubling of the Ap4 
content in wild-type cells treated with FK866 (Table 2). Such doubling was 
accompanied by the depletion of NMN and NAD, as expected, and by a marked 
reduction of Nam. These data, taken together, suggest that NAMPT is a source of 
intracellular Ap4, although we cannot rule out the possibility that other enzymes also 
contribute. The effect observed in the presence of FK866 could in part be explained 
by the uncoupling of the two reactions, as shown by the experiments performed on 
the purified enzymes, and in part could suggest that a cellular homeostatic control is 
present. Ap4 levels under conditions of metabolic perturbation were also evaluated. 
We assayed Ap4 levels in cells grown for 20 hr in serum-free conditions, in low-
glucose conditions (normal concentration of 4.5 g/L to a low concentration of 1 g/L), 
and in both low-glucose and serum-free conditions. Levels of Ap4 were reduced in 
all three conditions but were statistically reduced only when cells were grown in low 
concentration of glucose (Figure 6A). On the contrary, NMN levels were statistically 
reduced only when cells were grown in the absence of serum (Figure 6B). Treating 
cells with H2O2 (500 mM) reduced both Ap4 and NMN levels, but this change was 
not statistically significant. Furthermore, given the extracellular role of secreted 
NAMPT, we decided to explore whether we could detect Ap4 in murine plasma and 
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whether circulating NAMPT levels correlated with plasma Ap4 levels. To this end, 
we sampled blood from mice for both NAMPT (via an ELISA assay) and Ap4 levels 
(by LC-ESI- MS). In most samples Ap4 was detectable with a global mean of 562 ± 
114 nM (n = 23). This is similar to a previous report of Ap4 in human plasma at 
255.6 ± 82.4 nM28. In addition, these Ap4 levels, despite their inter- and intra-subject 
variability, showed a good correlation with extracellular NAMPT levels (Figure 6C, 
R2 = 0.41). Not surprisingly, Ap4 also correlated, to a greater extent, with ATP levels 
measured in parallel (Figure 6D, R2 = 0.81). These data are consistent with the notion 
that extracellular NAMPT may be one of the enzymes that participates in the 
synthesis of Ap4, and that Ap4 is derived enzymatically from ATP. 
 
 
Figure 5. Mouse B16 cells with modulated expression of NAMPT. Crude protein extracts were obtained from wild type B16 
cells or from the same cells after lentiviral transfection with either FLAG-NAMPT or shNAMPT Low constructs, respectively 
inducing a stable NAMPT over-expression or its silencing. After electrophoresis, membrane transfer, and immunostaining with 
specific antibodies (A), the NAMPT protein levels were quantified relatively to the housekeeping beta-Actin signal by 
densitometry analysis (B) 
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nmol/mg of protein 
B16 cells Ap4 ATP ADP Nam NMN NAD 
WT (n=9) 
0.527 
(0.068) 
9.107 
(1.595) 
8.992 
(2.056) 
4.344 
(0.721) 
0.039 
(0.007) 
4.489 
(1.524) 
WT +FK866 (n=7) 
0.923 
(0.101)** 
5.882 
(0.605) 
7.654 
(1.385) 
3.056 
(0.535) 
0.010 
(0.002)* 
Nd 
FLAG-NAMPT (n=3) 
1.073 
(0.175)** 
17.22 
(0.546) 
13.32 
(0.454) 
2.417 
(0.097) 
0.212 
(0.068)*** 
6.940 
(0.122) 
shNAMPT Low (n=5) 
0.329 
(0.075)ns 
5.347 
(1.027) 
5.972 
(1.125) 
3.281 
(0.311) 
0.026 
(0.005)ns 
2.135 
(0.289) 
 
Table 2. Adenylate and pyridine compounds in melanoma B16 cells with modulated intracellular expression of NAMPT (see 
Figure 5), or treated with 100 nM FK866 for 24 hours, were collected and evaluated for their nucleotides levels by LC-ESI-
MS analysis. B16 WT, wild-type cells. B16 shNAMPT Low, cells engineered for NAMPT silencing. B16 FLAG-NAMPT, 
cells engineered for NAMPT over-expression. Data are represented as the mean and SEM (in parentheses) from n experiments, 
as indicated. Statistical analysis for Ap4 values: p=0.09 (ns) for B16 shNAMPT Low cells vs B16 WT cells; p=0.0048 (**) for 
B16 FLAG NAMPT cells vs B16 WT cells; p=0.0047 (**) for B16 WT+FK866 cells vs B16 WT cells. Statistical analysis for 
NMN values: p=0.19 (ns) for B16 shNAMPT Low cells vs B16 WT cells; p=0.0009 (***) for B16 FLAG NAMPT cells vs 
B16 WT cells; p=0.045 (*) for B16 WT+FK866 cells vs B16 WT cells. Nd, below the detection limit 
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Figure 6. A and B. Ap4 (A) and NMN (B) levels evaluated by LC-ESI-MS in B16 wild-type cells under metabolism 
perturbations obtained by growth for 20 hr in serum (fetal bovine serum [FBS])-free conditions, in low-glucose (Low Glu) 
conditions (from 4.5 to 1.0 g/L), in both low-glucose and serum-free conditions, or treatment with 500 mM H2O2. *p = 0.05 
for Ap4 levels of B16 in Low Glu/+FBS condition versus ctrl cells; *p = 0.029 for Ap4 levels of B16 in Low Glu/FBS-free 
condition versus ctrl cells; *p = 0.03 for NMN levels of B16 in +Glu/FBS-free condition versus ctrl cells; *p = 0.05 for NMN 
levels of B16 in Low Glu/FBS-free condition versus ctrl cells. Values represent the mean + SEM from a triplicate assay. 
C and D. The Ap4 levels measured by LC-ESI-MS in the plasma of healthy male C57BL/6 mice (n = 23 total analyzed samples) 
and their correlation with extracellular NAMPT (C) and ATP (D). The linear regression value (R2) is highlighted 
3. Discussion: 
Ap4 was first described in the early 1950s as a contaminant of commercial ATP 
preparations35, and re-emerged in the literature about 50 years later as an 
extracellular vasoactive compound28,36. It has a broad distribution in prokaryotes and 
eukaryotes, including mammalian tissues and plasma, and has been identified as an 
in vitro by-product of a number of ATP-dependent enzymatic reactions29. Given the 
lack of any dedicated enzyme to its synthesis, Ap4 in vivo is thought to arise from 
the promiscuous activity of multiple enzymes, and no information about its 
physiological regulation is currently available. Yet, given that Ap4, at sub-
nanomolar concentrations, is one of the most potent vasoconstrictors known to 
date28, and nanomolar concentrations of Ap4 can modulate the intraocular pressure 
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in the rabbit eye36, it seems unlikely that its production would not be regulated. These 
actions of extracellular Ap4 are also mediated by P2X receptors28,36 that belong to a 
structural family of membrane ion channels, with a widespread tissue distribution in 
mammals, where they underlie a variety of functions, including excitatory effects on 
smooth muscle cells (depolarization/contraction), Ca2+ uptake into neurons 
(neuromodulator responses), and release of pro-inflammatory cytokines such as 
interleukin 1b from immune cells37. On the other hand, intracellular functions of Ap4 
are only putative at present but potentially relevant in fundamental biological 
processes like, for example, the cellular protein turnover, as suggested by the 
observed in vitro targeting of Ap4 to AMP-forming ligases, aminoacyl-tRNA 
synthetases38, and the ubiquitin-activating enzyme E1 of the proteasome system39.  
 
3.1 Mechanism of the enzymatic formation of Ap4 
To our knowledge, the data presented here establish for the first time that two 
enzymes belonging to the class of type II PRTases, long thought to be committed to 
NAD synthesis in living cells with a non-obligatory accompanying use of ATP, are 
also capable of synthesizing Ap4. We propose a mechanism shared by NAMPT and 
NAPT, where the known ATP hydrolysis is coupled to a new phosphor-transfer 
reaction that, via the same E-P complex intermediate, leads to Ap4 synthesis. 
Notably, the facultative ATPase of both enzymes has been extensively studied in the 
past as a paradigm for energy use11,14, but the reaction as such went partially 
unnoticed due to its cryptic nature and, most likely, to the lack of a stoichiometric 
evaluation of all reactants involved. Nevertheless, in support of our model, 
mechanisms similar to the proposed one apply to other enzymes forming covalent 
intermediates during their catalytic cycle. For example, glucose-6-phosphatase40, 
transglutaminases41, and nucleotidases42 are all known to catalyze branched-pathway 
reactions characterized by double-displacement mechanisms and formation of 
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covalently modified enzyme intermediates (phosphorylated or acylated) that 
preserve the transfer potential of the group undergoing transfer. 
One peculiarity of NAMPT and NAPT is that such use of ATP may occur 
independently from NMN/NaMN synthesis, the intrinsically catalyzed reaction for 
which they were originally classified and that remains the focus of most current 
studies. Notably, only NAMPTs and NAPTs from both bacterial and mammalian 
sources are known to use ATP hydrolysis and to catalyze a dual PRTase reaction, 
whether ATP coupled or ATP uncoupled11,13,17,43. The other classified PRTase 
members, including adenine (EC 2.4.2.7), hypoxanthine/guanine (EC 2.4.2.8), uracil 
(EC 2.4.2.9), orotate (EC 2.4.2.10), quinolinate (EC 2.4.2.19), and 
dioxotetrahydropyrimidine (EC 2.4.2.20) PRTases are widely considered to be ATP 
insensitive, albeit supporting experimental evidence exists in only a few cases44,45. 
To confirm this, we have tested the ATP dependence of a bacterial quinolinate 
PRTase and a member of the hypoxanthine/guanine PRTase family. The results 
showed the ATP insensitivity of both these PRTases (Figure 6A and 6B)31. It should 
also be noted that quinolinate PRTase, the closest functional and structural relative 
of NAMPT and NAPT1, lacks the conserved His residue that is essential for Ap4 
formation according to our scheme and catalyzes a reaction of irreversible nature due 
to a decarboxylation step occurring along with the phosphoribosyl transfer46, so that 
there is no need of ATP hydrolysis to drive the reaction. On the contrary, in both 
NAMPT and NAPT, ATP is used to establish the formation of a phosphohistidine 
intermediate10,12 that has been shown to potentiate their PRTase activity11,16, thereby 
enhancing cellular NAD synthesis. Nonetheless, in both NAMPT and NAPT, the 
reaction coupling ATP hydrolysis to NMN/NaMN synthesis is not stoichiometric 
and only a small part of the energy released from the hydrolysis is efficiently 
captured11,12. This appreciable thermodynamic leak suggests additional roles exerted 
by the facultative ATPase reaction, perhaps independent from coupling. In this 
regard, our finding that it may drive Ap4 synthesis is an intriguing explanation. This 
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is also supported by the observed catalytic similarity between mammalian and 
bacterial orthologs (Table 1), which suggests an intrinsic role for the Ap4 synthesis 
mediated by these enzymes, fully conserved throughout evolution. 
 
3.2 LC-MSn bioanalytical method development 
To quantify the intracellular levels of Ap4, ATP, ADP, Nam, NMN and NAD in both 
murine cells and murine plasma, a new LC-MSn bioanalytical method has been 
developed. The source parameters were set up according to the chemical features of 
the compounds. Ap4, ATP and ADP gave a better response in negative ionization 
mode, due to the phosphate moieties on their structures. While Nam, NMN and NAD 
gave better results in positive ionization mode due to the contemporary presence of 
pyridine and adenine moiety with the absence of free phosphate moieties which 
characterize their structures. MS/MS ion fragmentations were studied to develop a 
SRM or MRM scans for each analyte. Only for Nam, the scan performed was a 
MS/MS mode, cause the low mass of the analyte which made impossible to have a 
stabilization of the mother and daughter ions during the fragmentation (Figure 3). 
The Chromatographic conditions were optimized to satisfy these features: (1) good 
peaks shape; (2) retention times far enough from the death time of the column and 
not too high, to get a method as faster as possible; (3) to avoid matrix effects; (4) to 
have all the analytical parameters in the common ranges of agreement. 
Various stationary phases were tested (such as C18, C8, Biphenyl, F5, Synergy Polar 
and Kinetex HILIC) with various methods, without any success. In the end, we opted 
for a Luna HILIC column which, thanks to a silica surface covered with cross-linking 
diol groups, allows a polar selectivity under hydrophilic liquid chromatography 
conditions. In order to have satisfactory % matrix effects values, an isocratic run 
analysis was performed as described in the experimental section. Gradient elutions 
were tested but no one gave positive results under this aspect. In fact, matrix is 
constituted essentially by polar small molecules and salts which is important to keep 
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them separated from our analytes of interest, in terms of retention time. % matrix 
effects values were reported in Figure 4B.  
For what concern the sample preparation, the strategy chose to clean up the 
biological samples was the protein precipitation with organic solvents (ppt). It is a 
quick technique, not expansive and suitable for large batch of samples. The limiting 
point of this technique is that is not always the best option, cause it could be tricky 
to find out the right solvents and solvents ratio for having a good extraction. 
Nowadays, the ppt is the most common way to extract adenylate and pyridine 
compounds47, even if the recovery is not always greater than 80% for all the 
molecules studied. We developed two different ppt sample preparations for each 
matrix analyzed. The best conditions of ppt for having the highest % recovery values 
were used and the % recovery values were described in figure 4A. % recovery 
resulted slightly low for Ap4 and Nam. It could be due to the high polarity of both 
of these compounds, associated to the small structure of Nam. These facts could tend 
Ap4 and Nam to precipitate with the huge amount of protein in the matrices analyzed.  
The linearity was set using the external calibration method because all the analytes 
investigated are physiologically present in the cells or plasma samples. Nevertheless, 
the calibration curves of each compound were linear in the calibration range as 
demonstrated by the correlation coefficients reported in the last line of the table 
(Figure 4D). 
Each biological sample was analyzed in analytical triplicate.  
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3.3 In vitro and in vivo Ap4 production and modulation 
Focusing on murine NAMPT, whether as an intracellular enzyme acting in the 
amidated NAD-salvaging route3 that chiefly regulates NAD homeostasis7 or as an 
extracellular cytokine25,27, we provide evidence for an Ap4 synthesis of potential 
relevance at both the cellular and systemic level. First, the NAMPT ATPase is 
modulated in vitro by several compounds targeting the enzyme active site, 
suggesting a capability to synthesize Ap4 from ATP both intracellularly, in the 
presence of PRTase reactants, and extracellularly, in the absence of most of them48. 
Second, in vivo Ap4 levels correlate with intracellular and, to some extent, 
extracellular NAMPT expression levels (Table 2; Figure 6C), pointing that NAMPT 
may regulate Ap4 homeostasis in different mammalian tissues. Third, metabolic 
perturbation in cells is able to modulate both Ap4 and NMN synthesis, albeit to 
different extents (Figures 6A and 6B). Fourth, the treatment with FK866, a selective 
inhibitor of NAMPT PRTase, but not of NAMPT ATPase (Table 1), downregulates 
intracellular NAD levels9,49, but in contrast it upregulates intracellular Ap4 levels 
(Table 2). This latter observation further indicates that the intrinsic and facultative 
reactions catalyzed by NAMPT should be equally considered when investigating the 
effects of NAMPT inhibitors. 
Indeed, an additional finding from our work is that NAD and FK866 exert opposite 
effects on NAMPT regarding its Ap4 synthesis, respectively inhibiting or 
potentiating it. Both compounds target NAMPT at the active site but, while NAD 
competes with PRPP11, FK866 binds at the dimer interface and competes with Nam 
for binding1,49. In keeping with such distinct binding sites, we observed that FK866 
behaves like Nam in potentiating the ATPase activity, while NAD behaves like 
PRPP in preventing it. This leads to suggest that FK866 binding to the catalytic 
pocket of NAMPT, contrary to NAD binding, does not block ATP binding and its 
catalytic processing. Furthermore, as reflected by the picomolar versus nanomolar 
Ki values reported for FK866 and NAD, respectively11, we found that micromolar 
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concentrations of FK866 can neutralize the effect of millimolar NAD in vitro. 
Therefore, NAMPT targeting by FK866 results in a novel biological effect, i.e., the 
rise of physiological Ap4 levels, in addition to the well-documented NAD depletion 
effect. This should be taken into account when evaluating the actions of this drug. 
From the point of view of cell physiology, the coincidental identification of Ap4 
synthesis by NAMPT and NAPT might underlie a dual level regulation of NAD 
biosynthesis: a direct one, through the NMN/NaMN-forming activity, and an indirect 
one, through Ap4 signaling. In a plausible scenario, for example, Ap4 would reroute 
protein resources toward de novo NAD biosynthesis, which in mammals starts from 
tryptophan. Indeed, while inhibiting aminoacyl-tRNA synthetases38, Ap4 might 
support the activity of proteasome39, both processes converging in boosting 
tryptophan bioavailability. Speculation on the possible involvement of Ap4 in other 
intracellular pathways is hard to present at the moment, as the physiological targets 
for Ap4 are only putative.  
On the other hand, in an extracellular context, Ap4 has recognized functions on 
purinergic signaling. In the rabbit eye this established function might be related to 
local NAMPT35. Furthermore, our observation that ATP and Ap4 are both circulating 
in murine plasma, where NAMPT is also present (Figures 6C and 6D), confirms 
earlier reports28,48 and suggests the possibility that some extracellular functions of 
NAMPT might be based on its enzymatic synthesis of Ap4. In this light, it would be 
worth reassessing the reported cytokine-like functions of extracellular NAMPT12,50. 
The debate about the existence of a link between the molecular action and the 
enzymatic function of extracellular NAMPT is not yet settled, and our results provide 
new important elements that should not be overlooked. 
In conclusion, we have shown that NAMPT appears to be directly coupled to 
intracellular and/or extracellular Ap4 homeostasis in mammals. Given that both the 
intracellular and extracellular forms of this enzyme are recognized as relevant in a 
number of disease states51-53, and that Ap4 has been already recognized as a potent 
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signaling molecule, future work on this enzyme should not disregard this novel 
function. Further investigation should also encompass the other NAD biosynthetic 
enzyme, NAPT, endowed with the same catalytic property. 
4. Significance: 
This study reports additional catalytic properties of NAMPT and NAPT, two 
ubiquitous enzymes that are crucial for the synthesis of the essential redox co-factor 
NAD. They share structural similarity and dual location in mammals, i.e., both 
intracellular and extracellular. Extracellular NAMPT is also regarded as a cytokine 
endowed with multiple signaling functions, and whether its catalyzed reaction is 
pertinent to these actions is at present unclear, with contradictory evidence from 
different experimental settings. From a catalytic point of view, both NAMPT and 
NAPT appear profligate consumers of ATP. Indeed, they use a facultative ATP 
hydrolysis to promote their NAD biosynthesis activity by weak energy coupling. 
This paradigmatic reaction represents the main subject of our investigation. Our most 
significant finding is that bacterial and mammalian NAMPTs and NAPTs can also 
use ATP to form adenosine 5’-tetraphosphate (Ap4), a prominent signaling molecule 
of an as-yet unclear biochemical origin. Based on in vitro and in vivo evidence, we 
propose (1) a mechanism for Ap4 synthesis, (2) a chief contribution of NAMPT to 
Ap4 homeostasis in mammals, and (3) a reassessment of the NAMPT drug targeting 
in this light. Indeed, we demonstrate that in vivo targeting of NAMPT by FK866, a 
drug inhibitor of NAD synthesis, results in a parallel upregulation of Ap4 levels. This 
opens up pharmacological scenarios possibly missed before. In a broader 
perspective, a direct link of NAMPT to Ap4 formation suggests novel mechanisms 
by which this enzyme, intracellularly and extracellularly, may exert the plethora of 
actions that are attributed to it. 
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Material and methods: 
Experimental model and subject details: 
Cell Lines 
B16 cells were engineered for NAMPT over-expression or silencing as follows. To 
generate a stable B16 FLAG-NAMPT cell line overexpressing NAMPT, a FLAG-
NAMPT was cloned in the pLV-IRES-GFP bicistronic vector56. The lentiviral 
particles were produced in HEK293T cells transfected with pMDLg/pRRE, 
pMD2.VSVG, pRSV-Rev57, and pLVFLAG- NAMPT-IRES-GFP. Briefly, after 48 
h, the cell medium was collected, filtrated, and centrifuged at 100,000 x g for 90 min. 
The viral particles in the pellet fraction were titrated, resuspended at appropriate 
concentrations, and used to infect B16 cells. Likewise, a stable B16 shNAMPT Low 
cell line silencing NAMPT was obtained after B16 infection with lentiviral particles. 
These particles were produced as described above in HEK293T cells by using a 
second-generation packaging plasmid system added with GIPZ Mouse Nampt 
Lentiviral shRNA plasmid. The infected cells were sorted for high levels of GFP 
(GFP++, called B16 shNAMPT Low cells). All B16 cells were normally cultured in 
DMEM supplemented with 10 % fetal bovine serum (FBS), 2 mg/mL glutamine, 10 
U/mL penicillin and 100 lg/mL streptomycin. Typically, 1.5 x 106 cells were seeded 
and detached after 24 hours by trypsinization. When required, B16 cells were treated 
for 24 hours with 100 nM FK866. IC50 for FK866 on these cells is 122 nM at 72 
hours. For metabolism perturbation, cells were grown for 20 hours after adhesion in 
DMEM (4.5 g/L glucose) ± FBS, or MEM (1.0 g/L glucose) ± FBS. 
 
Animals 
Eight weeks old C57BL/6 healthy male mice were grown and treated under 
procedures authorized by the animal ethical committee of the University of 
‘‘Piemonte Orientale’’ (Novara, Italy). 
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Method details 
Preparative HPLC Chromatography 
The Ap4 from Jena Bioscience or from the ATPase assays described below was 
purified by HPLC onto a Tosoh Bioscience TSKgel DEAE-2SW (250346 mm) 
column. Elution was carried out at room temperature in volatile buffers, ammonium 
acetate 0.05M (A) and 1 M (B), at pH 5.5. The gradient applied at 1 mL/min flow 
rate was: 2.5 min at 25 % B; 23.5 min up to 60 % B; 2 min up to 100 % B; 4 min 
hold at 100 % B; 1 min down to 25 % B; 6 min hold at 25 % B. After subsequent 
injections of each sample in aliquots, the fractions corresponding to UV peaks 
eluting at  ̴ 22 min were pooled. The purified Ap4 was quantified from the Abs (260 
nm) using an ε(260 nm) of 15.4 mM-1cm-1, then frozen and lyophilized. 
 
Chemical and Enzymatic Digestion of the Purified NAMPT Product 
Following preparative HPLC chromatography, Ap4 amounts of 0.5, 1 and 2 nmol 
appropriately lyophilized in cleaned, acid-washed glass tubes, were ashed in a 
magnesium nitrate/ethanol solution58, before the chemically released organic Pi was 
quantified by Malachite green. A reference curve was created by treating in parallel 
pure ATP, ADP, and AMP (0.5 to 3 nmol each, from UV calibrated solutions). 
Alternatively, enzymatic digestions were carried out in either 0.3 mL mixtures 
containing ̴ 0.4 U/mL calf intestine alkaline phosphatase in the supplied buffer, or 
0.2 mL mixtures containing 0.04 mU/mL Crotalus adamanteus phosphodiesterase I 
in 0.1 M Tris/HCl buffer, pH 8.9, 0.1 M NaCl, 15 mM MgCl2. The mixtures 
contained 20-40 mM of purified Ap4 and were treated and analysed by C18-HPLC 
(see Activity assays). The commercial phosphodiesterase used was contaminated by 
a 5’-nucleotidase activity. 
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Cloning, Expression, and Purification 
The expression constructs used for mouse NAMPT and its H247E mutant are 
described in Grolla et al.33, those for human NAPT and its H213A mutant in Galassi 
et al.17, that for Acinetobacter baylyi NadV in Sorci et al.43, and that for 
Streptococcus pyogenes NadC in Sorci et al.55. The expression construct for 
Staphylococcus aureus PncB was obtained in this study by PCR amplification from 
genomic DNA and cloning into a pET-derived vector. Their transformation into E. 
coli BL21(D3) competent cells, expression by induction with IPTG 0.5 mM for 17h 
at 26-28 °C, and purification by TALON chromatography were carried out 
essentially as described in Orsomando et al.59. The purified enzymes were finally 
desalted on PD-10 in 50 mM HEPES/NaOH buffer, pH 7.5, 1mM TCEP, and stored 
at -80 °C. Their concentration was measured by the Bradford reagent protein assay. 
All these recombinant proteins were fused to N-terminal and/or C-terminal His-tag 
tails. 
 
Activity Assays 
One unit (U) is defined as the enzyme amount catalyzing 1 mmol/min product 
formation (or substrate consumption) at 25 °C. Rates were calculated in the linear 
region of v vs t plots (product accumulation versus time). The PRTase activities of 
NAMPT and NAPT (either NMN or NaMN synthesis) were measured by adapting a 
continuous assay based on detection at 340 nm of the NADH formed60 in the 
presence of PncC, NadD, NadE, and ADH as the ancillary enzymes4. The mixtures 
for NAMPT assay contained, in 0.5 mL final volume, 80 mM HEPES/NaOH buffer, 
pH 7.5, 12 mM MgCl2, 0.5 mg/mL bovine serum albumin, 75mM ethanol, 
30mMsemicarbazide, 4.5mM NH4Cl, 0.024 U/mL PncC, 0.192 U/mL NadD, 0.081 
U/mL NadE, 12.5 U/mL ADH, 1 mM ATP, 0.5 mM PRPP, 0.5 mM Nam, and 20-
40 mg/mL of enzyme to be tested. In NAPT assays, PncC was omitted, 50mM 
K2HPO4, pH 7.5, was included in addition
17, and Na 0.5mM was used in place of 
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Nam. The pyridine substrate was usually added to start the reaction and, when 
indicated, mixtures were supplied with 2.5 mL of 10 mM FK866 in DMSO (50 mM 
final). Alternatively, the ATPase activities of NAMPT and NAPT (either ADP or Pi 
or Ap4 synthesis) were measured by discontinuous assays. The assay mixtures 
contained, in 0.2 mL final volume, 50 mM HEPES/NaOH buffer, pH 7.5, 5 mM 
MgCl2, from 0.25 to 2.5 mM ATP, and from 0.03 to 2.3 mg/mL each enzyme (i.e. 
0.5-40 mM based on average MW). The enzyme or ATP were added to start the 
reaction and, when indicated, mixtures were supplied with 1 mL of 10 mM FK866 
in DMSO (50 mM final) or other compounds in water. During incubation, 20 µL 
aliquots were collected at different times and stopped on ice by addition of 10 µL 
HClO4 1.2 M. These aliquots were centrifuged, neutralized by addition of 6.8 µL 
K2CO3 1 M, and centrifuged again. For analytical purposes, the supernatants were 
injected into HPLC for separation and UV detection of both ADP and Ap4 formed, 
or treated with Malachite Green for VIS detection of the Pi formed58. In this latter 
case, they were quenched with two volumes of Biomol Green reagent, left for 15 min 
on the bench, and read at 620 nm. A calibrated solution of KH2PO4 was used for Pi 
quantitation. The HPLC analysis was carried out either by ion pair-reverse phase 
chromatography onto a Supelcosil LC18-S (250346 mm) column as reported3, or by 
the above anion exchange TSK-DEAE chromatography (see Preparative HPLC). 
Both HPLC methods allowed separation of Ap4, ATP, ADP, AMP, and adenosine, 
as verified by coelution with corresponding standards. The integrated peak areas 
were converted into nanomoles as described3, using the ε(260 nm) of 15.4 mM-1 cm-
1. Both NMN and NaMN after C18-HPLC were likewise quantified using an ε(260 
nm) of 3.5 mM-1 cm-1. 
 
Cell Extraction for Western Blot Analysis 
To monitor NAMPT expression and stability in the engineered cell lines B16 FLAG-
NAMPT and B16 shNAMPT Low, cultured cells were collected and lysed in a 20 
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mM HEPES/NaOH buffer, pH 7.5, containing 100 mM NaCl, 5 mM EDTA, 1 % 
Nonidet P-40, 1 mM PMSF, and appropriate aliquots of the Calbiochem Protease 
Inhibitor Cocktail Set VI. Proteins extracted were quantified by the BCA Protein 
Assay, separated on SDS-PAGE, blotted onto a nitrocellulose membrane, and 
stained with monoclonal antibodies specific for NAMPT and beta-Actin. 
Densitometry analysis was next performed with the Bio-Rad Quantity One program. 
 
Cell Extraction for MS Analysis 
The various B16 cells freshly grown and collected were frozen in liquid nitrogen and 
immediately lysed in 400 µL water/acetonitrile (1:3 vol/vol). Proteins were 
precipitated by centrifugation. The supernatant was treated in two different ways 
before LC-ESI-MS analysis. For quantification of Ap4, ATP and ADP, a 300 µL 
aliquot was evaporated in a rotational vacuum concentrator to dryness (for 4 h at 30 
°C) and reconstituted in 80 µL water/acetonitrile (1:1 vol/vol). For quantification of 
Nam, NMN and NAD, 80 µL of supernatant were directly analyzed. Values in nmol 
were referred to mg of protein extracted and quantified from the cell lysate. 
 
Mouse Plasma Sampling and Treatment 
From 3 mice, blood samples were drawn three times on separate days, while from 
other 14 mice, a single blood sample was collected. Before LC-ESI-MS analysis, 
100 mL of plasma were added to 300 µL of methanol, clarified by centrifugation, 
and then a 320 µL aliquot was evaporated to dryness and reconstituted in 80 µL 
water/acetonitrile (1:1 vol/vol). In parallel, 100 µL of plasma without dilution were 
used to quantify the extracellular NAMPT content by means of the NAMPT 
(Visfatin/PBEF) (mouse/rat) Dual ELISA Kit. 
 
 
 
Chapter 4 
120 
 
LC-ESI-MS analysis of Pyridine and Adenine Nucleotides 
Analyses were carried out onto a Thermo Finnigan LCQ Deca XP Plus system 
equipped with a quaternary pump, a Surveyor AS autosampler, and a vacuum 
degasser (Thermo Finnigan). The liquid chromatography was performed on a 
Phenomenex Luna HILIC column (150 x 2 mm, 3mm) with a Phenomenex Luna 
HILIC security guard column (4mmx 2 mm), at 25 °C, at 200 µL/min flow rate, 
under isocratic elution. The mobile phase was composed by a 70:30 (v/v) ratio of 
acetonitrile and 100 mM ammonium acetate buffer, pH 5.8. The injection volume 
was 5 mL and the run time was 20 min. The MS detection was performed using two 
different methods: negative polarity for Ap4 (SRM m/z 586 > 488 C.I.D. 25 eV), 
ATP (SRM m/z 506 > 408 C.I.D. 25 eV), and ADP (SRM m/z 426 > 328 C.I.D. 30 
eV), and positive polarity for Nam (MSMS m/z 123 C.I.D. 25 eV), NMN (SRM m/z 
335 > 123 C.I.D. 25 eV), and NAD (MRM m/z 664 > 542, 524 C.I.D. 25 eV). The 
instrument was set as follows: ion spray voltage, 4 kV; source current, 80 mA; 
capillary temperature, 350 °C; sheath gas flow (N2), 60 Auxiliary Units (A.U.); 
sweep gas flow (N2): 6.0 A.U., capillary voltage, -15.00 V (negative polarity) and 
18.00 V (positive polarity); tube lens offset, -5.0 V (negative polarity) and 10.00 V 
(positive polarity); multipole 1 offset, 7.50 V (negative polarity) and -5.00 V 
(positive polarity); multipole 2 offset, 11.00 V (negative polarity) and -8.00 V 
(positive polarity). 
 
Quantification and statistical analysis 
All data represent the mean and SEM or SD of at least 3 independent experiments. 
T test analysis was carried out by PRISM program. A p value ≤ 0.05 was considered 
as significant and indicated in figures with asterisks (*). LC-MS data were acquired 
and processed using the Xcalibur® software. For quantification of Ap4, ATP, ADP, 
Nam, NMN and NAD in cell extracts and plasma samples, calibration curves in the 
appropriate range were prepared (external calibration method) with a correlation 
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coefficient (R2) always > 0.99; data were corrected for recovery and matrix effect 
when present. 
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Abstract: 
Adult hippocampal neurogenesis (ahNG) in mammals is increased by several 
antidepressant drugs. Trazodone (TZD) is a multimodal antidepressant drug with a 
unique pharmacological profile. However, TZD effects on ahNG are still unknown 
and a new bioanalytical tool is essential to deeply understand its mechanism of action 
in neural progenitor cells (NPC). So, the aim of the work was to develop a new LC-
MS bioanalytical method for the quantification of serotonin (5-HT) extracellular 
levels in primary cultures of murine NPC exposed to different stimuli. For our 
studies, differentiation media of murine adult hippocampal NPC (ahNPCs) was 
collected and proceeded for the proteins removal through a protein precipitation step. 
The liquid chromatography was performed on a Phenomenex Luna HILIC column 
while the serotonin MS detection was carried out in single reaction monitoring mode. 
Some LC-MS method parameters where assessed, such as: Selectivity, LLOQ and 
LOD, Linearity, % Recovery and % Matrix Effect. The method was successfully 
applied for measuring 5-HT levels in extracellular media of ahNPC. The results 
collected allowed us to demonstrate that ahNPCs cells do synthetize, release and 
uptake, by expressed SERT, 5-HT. Indeed, irreversible inhibition of tryptophan 
hydroxylase, a rate-limiting enzyme in serotonin biosynthesis, resulted in 
undetectable extracellular levels of 5-HT. Moreover, 5-HT levels are increased in 
extracellular media when cells were treated with proneurogenic concentrations of 
TZD (100 nM; 1.25 ± 0.20 ng/mL, p = 0.07) and fluoxetine, FLX (1 M; 1.76 ± 0.10 
ng/mL, p < 0.01) vs basal vehicle conditions (0.86 ± 0.19 ng/mL). Nevertheless, 
SERT blockage cannot be considered the main mechanism with which TZD exerts 
its novel proneurogenic effects.  
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1. Introduction: 
Adult hippocampal neurogenesis (ahNG) is a key and hot topic in the neuroscience 
research1,2. The search for factors that modulate the birth of new neurons produced 
preclinical and clinical evidence. In fact, it has been demonstrated that the 
hippocampal neurogenesis is downregulated in stress and depression conditions3,4. 
Nevertheless, among multiple signals which are related to this process, the serotonin 
(5-hydroxytriptamine, 5-HT) homeostasis plays a key role. Indeed, in the case of 
depression, the chronic modulation by antidepressant agents that inhibit serotonin 
reuptake in synapsis, leads to an upregulation of neural progenitor cells (NPC) 
proliferation and neurogenesis5,6. In this context, in vitro studies on the murine adult 
hippocampal NPC (ahNPCs) could help in understanding the proneurogenic 
potential of antidepressant drugs and the underlying mechanisms. Trazodone (TZD) 
is a triazolopyridine derivate and can be recognized as the first multimodal 
antidepressant due to its activities on various targets7,8,9. So far, the potential 
proneurogenic effect of this compound has never been investigated.  
In literature various LC-MS methods are reported to quantify serotonin and other 
small molecules in biological matrices as cerebrospinal fluid10, rat brain tissue11, 
plasma12, blood13, serum14 and urine15. However, none of them deals with the 
analysis of extracellular differentiation media. So, in order to evaluate whether TZD 
proneurogenic effects require 5-HT synthesis by murine ahNPCs, the aim of the 
work was to develop a new LC-MS bioanalytical method to quantify 5-HT in 
extracellular media of murine ahNPCs. 
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2. Material and Methods: 
2.1. Reagents and chemicals 
The source of reagent and chemical was as follows: acetonitrile (HPLC grade), 
formic acid, 5-Hydroxytryptamine hydrochloride (5-HT) trazodone hydrochloride 
(TZD), DL-P-chlorophenylalanine (PCPA), and fluoxetine hydrochloride were 
purchased from Sigma-Aldrich (Milan, Italy). Water (HPLC grade) was obtained 
from Milli-Q RO system. 
 
2.2 LC-MS bioanalytical method 
LC-ESI-MS analyses were carried out using a Thermo Finnigan LCQ Deca XP Plus 
system equipped with a quaternary pump, a Surveyor AS autosampler and a vacuum 
degasser (Thermo Finnigan, San Jose, CA). The liquid chromatography was 
performed on a Phenomenex Luna HILIC column (150 x 2 mm, 3 µm) with a 
Phenomenex Luna HILIC security guard column (4 mm x 2 mm), at 25 °C, at 200 
µl/min flow rate, under isocratic elution. The mobile phase was composed by a 90:10 
ratio of acetonitrile and water (both with 0.2% v/v of formic acid). The injection 
volume was 5 µl and the run time was 20 min. The MS detection of serotonin was 
performed in positive ionization mode. Quantitation was carried out using single 
reaction monitoring (SRM) mode to monitor the transition m/z 177 > 160 (Collision-
Induced dissociation C.I.D. 20 eV). The principle instrument parameters were set as 
follows: ion spray voltage, 5.2 kV; source current, 80 µA; capillary temperature, 
350°C. 
 
2.3 Preparation of serotonin stock solution 
The stock standard solutions of the serotonin were prepared by dissolving its powder 
accurately weighted amounts (5.0 mg) in 5 ml of water (HPLC grade). The solution 
was kept in darkness at −24°C. This solution was stable for at least one month and 
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was diluted in water/acetonitrile with 0.2% formic acid (7:3 vol/vol). before the use 
to the required concentrations. 
 
2.4 LC-MS method parameters 
LC-MS bioanalytical method was assessed for the following parameters: Selectivity, 
Lower Limit of Quantification (LLOQ), Linearity, % Recovery and % Matrix Effect. 
 
2.4.1 Selectivity 
The LC-MS method selectivity has been evaluated by the injection of matrix blank 
samples arising from six different batches. The presence of matrix components, 
degradations products and impurities which may interfere with the analyte of interest 
has been investigated. 
 
2.4.2 Lower Limit of Quantification (LLOQ) and Limit of Detection (LOD) 
The determination of LLOQ and LOD was based on signal-to-noise ratio: this was 
evaluated by comparing measured signals from samples of Serotonin at low 
concentrations with those of blank samples and by establishing the minimum 
concentration at which the analyte can be quantified (LLOQ; S/N = 10) and the 
minimum concentration at which the analyte can be detected (LOD; S/N = 3). 
 
2.4.3 Linearity 
The linearity was performed using the internal calibration method. It assessed at six 
concentration levels in a range of 1 – 100 ng/mL by diluting the standard stock 
solution in differentiation media treated with acetonitrile with 0.2% formic acid (3:7, 
vol/vol). These points were injected in analytical triplicate and the peak areas were 
inputted into a Microsoft Excel® spread-sheet to plot calibration curves. 
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2.4.4 % Recovery (% RE) and % Matrix Effect (% ME) 
% Recovery and % Matrix Effect were evaluated at three concentration levels: 1 – 
50 – 100 ng/mL preparing three different samples starting from serotonin stock 
solution: (A) sample prepared in water/acetonitrile with 0.2% formic acid (7:3 
vol/vol); (B) sample prepared adding the standard to the blank matrix after the 
protein precipitation step; (C) sample prepared adding the standard to the blank 
matrix before the protein precipitation step. Then, % RE and % ME were calculated 
with the following formula: 
% 𝑅𝐸 =
𝐶
𝐵
 × 100 
% 𝑀𝐸 =
𝐵
𝐴
 × 100 
 
The matrix effect was evaluated also with the post infusion method16. Briefly, this 
method consists in the injection of a blank matrix samples on the LC column and at 
the same time in the continuously flow injection of the sample (A) directly in the ion 
source. There is an evaluation of the increasement and / or suppression of the signal 
caused by the matrix in proximity of the analyte retention time.  
 
2.5 Animals 
Male C57BL/6 (C57BL/6, The Jackson Laboratories, US) mice were acclimated 
under light- and temperature-controlled conditions in high efficiency particulate air 
(HEPA)-filtered Thoren units (Thoren Caging System, Hazelton, PA). Mice were 
housed in number of 3-4/cage with ad libitum access to food and water at the animal 
facility of Piemonte Orientale University. Animal care and handling were carried out 
according to protocols approved by the European Community Directive and the local 
Institutional Animal Care and Use Committees (IACUC). 
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2.6 Isolation and Culture of Adult Hippocampal Neural Progenitor Cells (ahNPCs) 
Adult murine hippocampal NPC isolation was performed as previously described17. 
Briefly, for each culture preparation three adult male mice (3-4 months-old) were 
euthanized by cervical dislocation, and their hippocampi dissected. Tissue was 
digested by a Papain Dissociation System (Worthington DBA, Lakewood, NJ). Cells 
were plated in NUNC EasyFlask 25 cm2 (Thermo Scientific, Waltham, MA) and 
cultured in serum-free complete proliferation medium [Neurobasal-A with B27 
supplement, 2 mM glutamine (Gibco, Life Technologies, Monza, IT), 20 ng/ml 
recombinant human Epidermal Growth Factor (rhEGF), 10 ng/ml of recombinant 
human Fibroblast Growth Factor-2 (rhFGF-2, PeproTech, Rocky Hill, NJ) and 4 
μg/ml heparin sodium salt (Sigma-Aldrich)]. Passage 1 (P1) neurospheres were 
dissociated for the first time after ten days in vitro (DIV). From P2, dissociation was 
performed every five days and NPC were replated at a density of 12,000 cells/cm2. 
NPC were used for proliferation and differentiation experiments from P5 to P30. 
Proliferating NPC were routinely tested for their undifferentiated state by expression 
of SOX2 (Sry-related HMG box transcription factor) and nestin (Type VI 
intermediate filament). For irreversible inhibition of tryptophane hydroxylase 
(TPH), cells were treated with 50 μM of PCPA or vehicle for 72 hours starting from 
the second day after dissociation. At day 5, cells were dissociated and plated for 
differentiation. 
 
2.7 Sample preparation for LC-MS analysis 
Vehicle- or PCPA-treated ahNPC were differentiated in presence of vehicle, 
trazodone or fluoxetine. Differentiation media were collected after 24 hours and 
centrifuged for 10 min at 16,000 g. 140 μl of acetonitrile with 0.2% of formic acid 
were added to 60 μl of collected media. Proteins were precipitated by centrifugation 
for 10 min at 11,300 g. An aliquot of 180 μl of supernatant was evaporated to dryness 
in a rotational vacuum concentrator (for about 4h at 40 °C). The sample was 
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reconstituted in 80 μl of water/acetonitrile with 0.2% of formic acid (3:7 vol/vol), 
before the injection. For quantification of serotonin in differentiation medium, a 
calibration curve was prepared in blank matrix (differentiation medium treated with 
acetonitrile with 0.2% of formic acid, 3:7 vol/vol) in the appropriate range. 
 
2.8 Statistical analysis 
All experiments were run in triplicates using different cell preparations and repeated 
at least three times. Data were expressed as mean ± S.D. and analyzed by one-way 
analysis of variance (ANOVA), followed by Tuckey’s post-hoc test or by Student’s 
t test. Statistical significance level was set for p values < 0.05. 
 
3. Results and discussion: 
3.1 LC-MS bioanalytical method development 
To quantify 5-HT extracellular level of murine adult hippocampal neural progenitor 
cells (ahNPCs), we developed a new LC-MS bioanalytical method. MS source 
conditions were set up by flow injection analysis of serotonin standard. Analyses 
were performed in positive ionization mode working in low mass range (< 250 u), 
considering the low M.W. of 5-HT. Fragmentation mechanism of serotonin has been 
investigated in order to select the best fragmentation reaction to set up an appropriate 
Single Reaction Monitoring (SRM) scan suitable for a quantitative study. A 
collision-induced dissociation energy was optimized at 22 eV on mother ion m/z 177 
[M+H]+ to monitor daughter ion m/z 160 [M+H]+. The full MS, MS2 and MS3 
spectra are reported in Figure 1.  
During the development of the chromatography part of the method, different 
stationary phases were considered and tested. Lipophilic stationary phases were 
excluded, and the attention was focused on the polar one due to the polarity moieties 
and the small dimension of 5-HT. Phenomenex Synergy Polar, Phenomenex Kinetex 
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F5, Phenomenex Luna HILIC an Phenomenex Kinetex HILIC were tested. Best 
results in term of retention time, peak shapes and matrix effect were obtained with 
the Phenomenex Luna HILIC (150 x 2 mm, 3 µm). Its polar selectivity under 
hydrophilic liquid chromatography conditions was essential to increase the serotonin 
retention time, and so to avoid matrix effect. The main media components, which 
may cause a matrix effect, have a retention at the death time of the column thanks to 
their high polarity. The mobile phase was composed by eluent A: water with 0.2% 
formic acid and eluent B: acetonitrile with 0.2% formic acid using an isocratic 
method (A/B, 90/10, vol/vol). The flow rate was 200 µl min-1 and the elution was 
kept at 25°C. Some Gradient elution was tested increasing the phase B during the 
time. We did not obtain positive results, mainly in term of matrix effect. 
Nevertheless, the run time was 20 min to allow all the matrix components to eluate 
out of the column and to avoid interference signals from the previous analytical run. 
We report an LC-MS chromatogram of serotonin with the method developed in 
Figure 1.  
The sample preparation was developed with the aim to have a quick, reproducible 
and in expensive procedure, which allows a full recovery in terms of serotonin. There 
are different techniques for cleaning the biological samples and for extracting 5-HT 
from biological samples like the protein precipitation from rat brain18,19, plasma20, 
platelet depleted plasma21, CSF10,22, serum22,14, the solid phase microextraction from 
CSF23, the solid phase extraction24-27 for urine and liquid-liquid extraction for rat 
brain tissue28,29. 
In this context, the approach chosen to clean up the extracellular media was a protein 
precipitation (ppt) step with acetronitrile 0.2% formic acid. For 60 µL of collected 
media, 140 µl of ppt solvent was added. This ratio between media and organic 
solvent is the result of the optimization process. High amount of acetonitrile gave 
bad results in terms of recovery. At the same time, less amount of acetonitrile did not 
allow a good protein and matrix components precipitation. 0.2% formic acid 
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increased the precipitation in all tested conditions. Moreover, an evaporation step 
was included in the sample preparation protocol, useful to concentrate the biological 
sample before the injection. This approach allows a satisfactory % RE for the 
serotonin extraction. 
 
 
Figure 1. LC-MS chromatogram, ESI + full mass, ESI + MS2 and ESI + MS3 spectra of 5-HT 
 
3.2 LC-MS bioanalytical method parameters 
Before analyzing the biological samples, the LC-MS method was assessed for the 
following method parameters: Selectivity, Linearity, LLOQ and LOD, % RE and % 
ME. 
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3.2.1 Selectivity 
As shown in Figure 1, The LC-MS method resulted selective for Serotonin. In 5-HT 
scan there are not any media components, degradation products of impurities which 
interfere with the serotonin peak. 
 
3.2.2 LLOQ and LOD 
LLOQ and LOD were established in 1.00 ng/mL and 0.30 ng/mL, respectively. It is 
reported in literature other LC-MS bioanalytical methods with even lower 
values20,30,31. At the same time, the LLOQ and LOD values reached with this method 
are more than enough to apply it for the study of ahNPCs extracellular concentration 
of serotonin. 
  
3.2.3 Linearity 
The linearity was set using the internal calibration method. The linearity of the 
method was calculated as unweighted linear regression y = ax + b. Nevertheless, the 
serotonin calibration curve was linear in the calibration range as demonstrated by the 
correlation coefficient greater than 0.999. All the data regarding the linearity were 
summarized in Table 1. 
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Linearity data 
Analyte Serotonin 
Range 
(ng/ml) 
1-100 
Slope (m) 35381.7 
Intercept (q) -321.3 
R2 0.9992 
LLOQ 
(ng/ml) 
1.00 
LOD(ng/ml) 0.30 
 
Table 1. Linearity, LLOQ and LOD data 
 
 
3.2.4 % Recovery and % Matrix Effect 
% Recovery and % Matrix Effect are reported in Figure 2A. All the % RE collected 
at three different levels of concentration were greater than 77 %. So, all of the 
recovery values were satisfactory, meaning that the serotonin extraction procedure 
from extracellular media is working properly. Also the % ME show good values, all 
of them greater than 82 % meaning that there is not an increase or a suppression due 
to the matrix on serotonin signal in the LC-MS run. The matrix effect has been 
evaluated also with the post infusion method as described by Matuszewski et al.16 
Also in this case, the matrix effect could be considered more or less of the 10 %, and 
so negligible. 
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Figure 2. (A) % RE and % ME of serotonin at three different levels. (B) ME evaluated with the post infusion method 
 
3.3 LC-MS bioanalytical method application 
The LC-MS method developed was applied to quantify the extracellular levels of 5-
HT in primary cultures of ahNPC in presence of different drugs including exposure 
for 24 h to trazodone and, as a control, fluoxetine (FLX). All the data regarding cell 
treatment with antidepressant drugs are described by Bortolotto et al.7 The same 
paper establish, for the first time, the in vitro proneurogenic effects of TZD at 
therapeutically relevant concentrations. With the results collected from the LC-MS 
experiment (Figure 3), we demonstrated: 5-HT levels are increased in extracellular 
media when cells were treated with TZD (1.25 ± 0.20 ng/mL, p = 0.07) and FLX 
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(1.76 ± 0.10 ng/mL, p < 0.01) in proneurogenic concentrations vs vehicle-treated 
conditions (0.86 ± 0.19 ng/mL). According to this data, fluoxetine (a selective 
serotonin reuptake inhibitor) treatment showed a statistically significant increase in 
terms of extracellular serotonin levels, as expected by its established ability to block 
SERT. Nevertheless, although serotonin extracellular levels are increased in TZD 
treatment conditions, there is not a statistically significant difference against vehicle 
condition (p > 0.05). According to this data, we could propose the following: (1) 
SERT blockage cannot be established as a major mechanism by which TZD exerts 
its proneurogenic effects. (2) Para-chlorophenylalanine (PCPA) treatment reduced 
5-HT extracellular levels, making them undetectable (< 0.3 ng/mL, LOD). PCPA is 
a selective and irreversible inhibitor of tryptophan hydroxylase, a rate-limiting 
enzyme in serotonin biosynthesis. So, cellular enzyme blockade resulted in depletion 
of serotonin in the extracellular culture media.  
Finally, taking together all of these results, we demonstrated that ahNPCs cells do 
synthetize and release in the extracellular compartment 5-HT which can also be taken 
up by SERT expressed on these cells.   
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Figure 3. LC-MS analysis of extracellular 5-HT content in our in vitro model under basal conditions and after treatment with 
1 μM FLX, 100 nM TZD and 50 µM PCPA 
 
4. Conclusion: 
In this work, it is described a new LC-MS bioanalytical method for the quantification 
of serotonin extracellular levels. This method has been successfully applied on 
murine ahNPCs exposed to different antidepressant drugs vs basal conditions. 
Thanks to this protocol some biological aspects regarding TZD proneurogenic 
mechanism of action were elucidated.  
Analyte Samples Conc  sd (ng/mL) p value
Serotonin
Veh 0.86  0.19 -
TZD 100 nM 1.25  0.20 0.07
FLX 1 µM 1.76  0.10 < 0.01 **
PCPA 50 µM n.d. -
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Abstract: 
Nicotinamide phosphoribosyltransferase (NAMPT) is a key enzyme involved in 
nicotinamide adenine dinucleotide (NAD) salvage pathway. NAMPT is a 
homodimer, that catalyzes the ratio of formation of NMN, precursor of NAD, and 
by doing so is the bottleneck enzymes in this pathway.  
 In literature, only two post-translational modifications on NAMPT have been 
described: the his247 autophosphorylation and the lys53 deacetylation. Surprisingly, 
no data are available on its phosphorylation sites. Since it is well known that 
phosphorylation controls the switch-on or switch-off of several enzymes, the aim of 
our work was to identify, quantify and characterize possible NAMPT phosphorylated 
sites in murine melanoma cells (B16 cells). Interesting, thirteen phosphorylated sites 
were identified and label free quantified by LC-MS based proteomics. Based on 
quantitative data, S199, S200 and S472 NAMPT phosphorylated sites were the more 
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abundant and by mutagenesis we have characterized at biological level the 
contribution of each phosphorylation. The mutant S199/200A showed significant 
differences vs NAMPT WT in terms of intracellular localization in melanoma cells, 
enzymatic activity and dimer formation as recombinant protein, suggesting a 
possible role of this PTM in controlling both location and the NAMPT enzymatic 
activity. 
This work has identified for the first time that NAMPT is phosphorylated and that 
this phenomenon may regulate its function and intracellular signaling. 
 
1. Introduction: 
Nicotinamide phosphoribosyltransferase (NAMPT) is a dimeric class of type II1 
phosphoribosyltransferase, made up of 491 amino acids and a molecular weight 
approximal of 55 kDa2. NAMPT does exist as an intracellular (iNAMPT) and 
extracellular (eNAMPT) form3. iNAMPT is localized mainly in cytosol, present in 
the nucleus and its presence in mitochondria is still uncertain and controversial4,5. 
eNAMPT has been described for the first time by Samal at al. in 19946 and it is 
known to be a cytokine7,8,9.  
NAMPT is the rate-limiting enzyme that contributes to the nicotinamide adenine 
dinucleotide (NAD) homeostasis in both prokaryotes and eukaryotes10. NAD may be 
synthetized from various sources such as tryptophan, nicotinic acid, nicotinamide 
riboside and nicotinamide, and the pathway11,12.    
NAMPT, which is involved NAD salvage pathway, catalysis the PRTase reaction 
that leads to the synthesis of nicotinamide mononucleotide (NMN), transferring a 
phosphoribosyl group from 5-phosphoribosyl pyrophosphate (PRPP) to 
nicotinamide (Nam). Afterwards, NMN adenylyltransferase (NMNAT) synthesizes 
NAD from NMN. Both the reactions are performed together with a facultative 
hydrolysis of ATP (ATPase)13,14. 
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Recently it was attributed to NAMPT a new phosphotransfer reaction which allows 
the synthesis of adenosine 5’-tetraphsphate, known as Ap4, in both in vitro and in 
vivo studies15. NAMPT is involved in many inflammatory and metabolic diseases, 
including cancer16, such as melanoma17,18,19, breast20, ovarian21, lymphomas22, 
myelofibrosis23, prostate24, gastric25 and colorectal cancer26,27. Indeed, NAMPT is 
over-expressed and released as eNAMPT by most of tumor cells and its high levels 
are correlated to prognosis and overall survival28.  
Nevertheless, in literature are reported only two post-translational modifications 
occurring on NAMPT, the histidine 247 autophosphorylation29 and the of lysine 53 
deacetylation30. The first one was well characterized by Burgos et al., and it increases 
the Nam affinity to the substrate binding site causing 1000-fold increased NMN 
production. The second one was reported by Yoon et al., 2015 and it is responsible 
of increasing NAMPT activity and in the secretion of NAMPT in the extracellular 
space.  
However, there are not evidences of NAMPT phosphorylated sites. Phosphorylation 
is surely one of the most important among the post-translational modifications. It 
plays key roles in the regulation of many cellular processes (e.g. cell cycle, growth, 
apoptosis and signalling).  
In this scenario, the aim of the work was to identify, to quantify and to characterize 
NAMPT phosphorylation sites in murine melanoma cells (B16-F10 cells). 
 
2. Results and Discussion:  
2.1 Identification and label-free quantitation of NAMPT phosphorylated sites in 
mouse B16 WT cells 
LC-MS based proteomics was the technique chosen for the identification of NAMPT 
phosphorylated sites in mouse GFP-NAMPT B16 cells. We chose B16 as model 
because in these cells NAMPT is over-expressed in basal concentration. Our model 
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has been engineered in order to have a stable expression of GFP fused at N-terminal 
of NAMPT. The cells conditions were set up as following: untreated cells, starvation 
(serum-free cells culture media) for 24 h, starvation for 24 h followed by 2 h of 
complete culture media and protease inhibitors cocktail. 
Two different samples preparation protocols were developed. After treatments, cells 
were harvested, lysed and NAMPT was immunoprecipitated (IP) with GFP traps. 
Beads were eluted, and samples were split to perform in solution trypsin digestion31 
and in gel trypsin digestion32. 
We identified thirteen phosphorylated sites in mouse B16 WT cells (Figure 1) by 
LC-MS with a Data Dependent Acquisition mode. The sites identified with two 
different protocols are slightly different. Only two sites (S472 and Y240) were 
identified with both samples preparation approaches. The differences of modified 
sites identified could be due to the different lysis buffers and proteases and 
phosphatases inhibitor cocktails used during the experiments. Moreover, cells were 
growth and harvested in two different laboratories.  
 
 
 
Figure 1. NAMPT phosphorylated sites identified in melanoma B16 GFP-NAMPT WT cells by LC-MS based proteomics 
analysis. Thirteen sites were identified performing two different lysis protocols starting from tissue cultures 
 
MS/MS spectra of all the phosphorylated peptides are shown in Figure 2. Data 
arising from PTMs confirm the identification of the modified sites.  
ID in sample preparation 2
ID in sample preparation 1S472
Y240
S398
T406
Y175
T220
S248
T249
S379
S200
S199
T218
S241
Chapter 6 
156 
 
 
Figure 2. MS/MS Higher-energy Collisional Dissociation (HCD) spectra of phosphorylated NAMPT peptides identified by 
mass spectrometry 
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++++
m/z 566.5162
D P V P G Y S V P A A E H S T I T A W G K  
y1y4y5y6y8 y2y3y15
b7
DPVPGYSVPAAEHS[+80]TITAWGK ++++
m/z 566.5162
D P V P G Y S V P A A E H S T I T A W G K  
y1y4y5y6y7y9 y2y3
b7 b19b13
GVS[+80]SQETAGIGASAHLVNFK+++
m/z 684.9965
G V S S Q E T A G I G A S A H L V N F K
y1y4y5y6y7y8 y2y3y12y13y14y15 y9y10
b2 b4b3
y11
GVSS[+80]QETAGIGASAHLVNFK+++
m/z 684.9965
G V S S Q E T A G I G A S A H L V N F K
y1y4y5y6y7y8 y2y3y12y13y14y15 y9y10
b2 b4b3
y11
b5
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Starting from the same cells and treatments, we analyzed in solution digested 
samples coming from both sample preparation protocols by LC-MS in Parallel 
Reaction Monitoring mode (PRM). Target modified peptides were label-free 
quantified and the area ratio x103 values are reported in table 1.  
 
 
Table 1. Label-free quantitation of thirteen NAMPT phosphorylated sites. Data were collected by LC-MS analysis with PRM 
acquisition mode of the target modified peptides. The average area of three unmodified NAMPT peptides acquired in PRM 
were used for the normalization of phosphorylated peptides area 
 
Each phosphorylated site has a phosphorylation trend through each treatment. S472 
is highly expressed in all the conditions tested even if the trend is different between 
the two protocols. Also, S199 and S200 are highly phosphorylated, and together with 
S472 revealed an interesting phosphorylation increasement in starvation condition 
vs untreated samples.  
In general, other sites resulted to be quantified in low amounts against the total 
NAMPT present in each sample. Considering the area values collected from these 
modified sites, it is difficult to appreciate significant differences between the 
treatment conditions.  
 
 
 
Peptide modified aa mod
Sample preparation 1 Sample preparation 2
Area ratio x103 Area ratio x103
BASAL Pinhib STAR STARfbs BASAL Pinhib STAR STARfbs
SYS[+80]FDEVRK S472 1.09 1.24 1.26 1.23 2.81 1.87 3.10 3.84
DLLNC[+57]S[+80]FK S398 0.10 0.13 0.17 0.05 0.17 0.28 0.45 0.28
C[+57]SYVVT[+80]NGLGVNVFKDPVADPNK T406 0.05
Y[+80]LLETSGNLDGLEYK Y175 0.26 0.07 0.15 0.22
GT[+80]DTVAGIALIK T218 0.15 0.15 0.21 0.13 0.02 0.15 0.24 0.13
GTDT[+80]VAGIALIK T220 0.12 0.14 0.17 0.09 0.02 0.17 0.01 0.02
KWSIENVS[+80]FGSGGALLQK S379 0.02 0.02 0.05 0.02 0.01 0.04 0.01
DPVPGY[+80]SVPAAEHSTITAWGK Y240 1.85 2.36 1.19 1.25 0.41 2.34 0.07
DPVPGYSVPAAEHST[+80]ITAWGK T249 0.02 0.59 0.01
DPVPGYS[+80]VPAAEHSTITAWGK S241 1.84 2.22 2.10 1.31 0.19 0.02 0.04
DPVPGYSVPAAEHS[+80]TITAWGK S248 0.06
GVSS[+80]QETAGIGASAHLVNFK S200 2.94 5.10 4.51 6.26 0.16 0.85 0.08
GVS[+80]SQETAGIGASAHLVNFK S199 2.68 4.58 4.13 5.48 0.15 0.95 0.08
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2.2 NAMPT localization in mouse B16 WT cells in starvation conditions 
NAMPT intracellular localization is known and it is already reported in literature4,5. 
With the aim to deeply study NAMPT localization under various stimuli, we started 
investigating the NAMPT intracellular localization of GFP-NAMPT in mouse B16 
WT cells in starvation conditions by laser confocal scanning microscopy analysis 
(Figure 3). Data confirm that NAMPT in untreated conditions is mainly localized in 
cytosol. It is interesting that NAMPT starts moving to nuclei after 8 h of starvation. 
Moreover, NAMPT remains localized in nuclei in the next time points checked at 17 
h and 24 h. 
 
 
Figure 3. Intracellular NAMPT localization in B16 GFP-nampt WT cells in starvation conditions. We evaluated NAMPT nuclei 
and cytosol localization in basal conditions (0h starvation), and after 4 h, 8 h, 17 h and 24 h using confocal microscopy    
 
Taking together the data arising from S472, S199 and S200 phosphorylation in B16 
WT cells and NAMPT intracellular localization in starvation, we decided to perform 
LC-MS targeted analysis to study NAMPT phosphorylation trends in nuclei and 
cytosol fractions of B16 WT cells in starvation conditions. 
We set up four experimental conditions: untreated, starvation 8 h, starvation 16 h and 
24 h starvation. After harvesting cells, we fractionated nuclei and cytosol and 
performed the IP with GFP traps (Figure 4A and 4B). After beads elution, samples 
were in solution trypsin digested and they were analysed by LC-MS in PRM 
B16 GFP-NAMPT cells
0 4 8 17 24(h)
Starvation
GFP
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acquisition mode. Quantitative results of S472, S199 and S200 modified sites are 
reported in Figure 4C. S472 phosphorylated site was statistically significant 
increased in starvation conditions vs basal conditions. In particular, both nuclei and 
cytosol after 8 h of starvation (p ≤ 0.05 and p ≤ 0.01, respectively), in cytosol after 
16 h (p ≤ 0.05) and in cytosol after 24 h (p ≤ 0.05). These data suggest that S472 is 
extensively phosphorylated in starvation conditions. Moreover, even more 
interesting is the phosphorylation trend of S199 and S200 phosphorylated sites. In 
cytosol, the quantitative data show a reduction of the phosphorylation till to be 
significative after 24h of starvation vs untreated condition (p ≤ 0.05). While, S199 
and S200 were detected in nuclei after 24h of starvation. The observations made in 
this multi time points starvation study could mean that the phosphorylation of S199 
and S200 sites is related to NAMPT intracellular localization. 
The study of these post translational modifications in transfected stable NAMPT 
S472A/D or S199/200A/D in B16 WT cells could elucidate their molecular 
significance. 
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Figure 4. NAMPT Phosphorylation trends in nuclei and cytosol of B16 WT cells in basal and starvation conditions. a) Cytosol 
and nuclei fractionation efficiency were monitored immunoblotting the IP samples with antibody anti-Vinculin and anti-H2A, 
respectively. b) Immunoprecipitation was checked immunoblotting Pre IP, Flow through IP and GFP IP samples with antibody 
anti-GFP. Both cytosol and nuclei samples were evaluated. c) The proteins collected from GFP IP samples were precipitated, 
in solution trypsin digested, desalted and analysed by LC-MS in PRM acquisition mode for phosphorylated peptides containing 
S472, S199 and S200 Phosphorylated sites. In the graphs are reported the area ratio x103 of phosphorylated peptides against 
the average of the area values of three NAMPT unmodified peptides collected using the label free quantitative approach. 
Statistical analysis of area values was carried out by applying t-test analysis. P value ≤ 0.05 was considered as significant and 
indicated in figure with one asterisk (*). P value ≤ 0.01 was considered as significant and indicated in figure with two asterisks 
(**).  
The experiment was performed in biological replicates and analytical duplicate each 
 
2.3 Preliminary studies of NAMPT mutants in mouse B16 WT stable cells and as 
recombinant proteins 
Given the LC-MS results we decided to proceed performing the site specific 
mutagenesis of the S472, S199 and S200 sites replacing serine with alanine to mimic 
the absence of phosphorylation or with aspartic acid to mimic the presence of 
A
B
C
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phosphorylation33. All of these mutations were performed in two different vectors: 
pLV-GFPnampt and pET28A-nampt. The first one is a lentiviral vector bringing a 
GFP N-terminal fused NAMPT sequence useful for transfecting HEK293 and then 
infecting B16 WT cells to make stable NAMPT mutants cells. The second one was 
used for inducing the NAMPT mutants expression in BL-21 bacteria with the aim to 
purify recombinant NAMPT mutant proteins.  
The data reported subsequently could be considered as preliminary data. Currently, 
only S472A, S199/200A mutants have been investigated. At the beginning, we opted 
to mutate in the same vector both S199/200A to assess whether any differences 
between the mutant and the WT, with the aim to study each mutation individually in 
case of promising results.  
  
2.3.1 Intracellular localization of NAMPT mutants in mouse B16 WT stable cells 
We studied NAMPT localization of NAMPT WT, NAMPT S199/200A and NAMPT 
S472A in mouse B16 WT cells in basal condition without treatments. Images took 
by laser confocal scanning microscopy analysis and the number of cells counted for 
NAMPT localization are reported in Figure 5. As confirmation, NAMPT WT is 
localized mainly in cytosol. NAMPT S472A is localized predominantly in cytosol 
with an overlapping behavior of NAMPT WT, as demonstrated by the cells counts. 
NAMPT S199/200A is localized in nuclei.  
The residue S472 is exposed on the surface of NAMPT, and it does not seem 
affecting NAMPT intracellular localization. While S199 and S200 residues are in the 
area of dimerization of NAMPT (Figure 6). 
The absence of phosphorylation in NAMPT S199/200A mutant or the absence of 
serine hydroxyl free moiety could be responsible of nuclear localization of the 
protein.    
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Figure 5. NAMPT WT, NAMPT S199200A and NAMPT S472A intracellular localization in B16 WT cells in basal condition. 
NAMPT mutant localization were evaluated in three stable cells lines: B16 GFP-nampt WT, B16 GFP-nampt S199200A and 
GFP-nampt S472A. Intracellular NAMPT localization was described as nuclear, cytosolic or both for unspecific localization 
 
NAMPT S472A
NAMPT S199200A
NAMPT WT
Localization WT S199200A S472A
Nuclei (N) 2 100 5
Cytosol (C) 31 - 34
Both (B) 25 6 29
Total 58 106 68
COUNTS
mergenucleiGFP
N
C
B
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Figure 6. NAMPT dimer quaternary structure. In red is highlighted S472 amino acid and in green are highlighted S199 and 
S200 amino acids on both NAMPT monomers  
 
2.3.2 Enzymatic activity of NAMPT mutant recombinant proteins 
We investigated also the enzymatic activity of NAMPT WT, NAMPT S472A and 
NAMPT S199/200A recombinant proteins. To perform this analysis, we reproduced 
the in vitro NAMPT enzymatic assay.29 For each recombinant protein, we tested their 
enzymatic activities at five concentrations, maintaining fixed the substrates amounts. 
Results are plotted in graphs in Figure 7A and 7B. The data shown that the enzymatic 
activity of NAMPT S472A is similar to the one of NAMPT WT. While NAMPT 
S199/200A is complete inactive, also at very high concentration.  
The results collected indicate that the mutation S472A is not influencing the intrinsic 
activity of the enzyme in producing nicotinamide mononucleotide (NMN). While, it 
is clear that S199/200A double mutations is affecting heavily the enzymatic 
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production of NMN. Probably, it could be due to the unfolding of the NAMPT dimer 
structure, that again could be missing for this mutant. 
It is important to highlight that we have not evaluated the kinetic of the reactions, so 
far. We can suppose that by performing a kinetic experiment altering the substrates 
concentration, we could better shed light on this aspect.   
     
 
Figure 7. Enzymatic activity of mouse NAMPT WT, NAMPT S199200A and NAMPT S472A recombinant proteins. The 
enzymatic assay is performed at five different enzyme concentrations (1µg, 2µg, 3µg, 5µg, 10µg) in biological replicate and 
the averages absorbance were used. Absorbance values were revealed at 455nm wavelength each 2.5 minutes. a) Absorbance 
values are plotted per each NAMPT mutant. b) Absorbance values are plotted per each enzyme concentration. The experiment 
was performed in biological replicate 
 
2.3.3 Investigation of NAMPT dimer formation of NAMPT mutants recombinant 
proteins  
Considering the results obtained about the intracellular localization of NAMPT 
mutants and their enzymatic activity, we next tested the NAMPT dimer formation of 
NAMPT recombinant mutants since its dimerization is essential to guarantee its 
A
B
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enzymatic efficiency.29 To evaluate this aspect, NAMPT WT, NAMPT S472A and 
NAMPT S199/200A recombinant proteins were incubated with bissulfosuccinimidyl 
suberate (BS3), a well-known crosslinker with the ability to cross-link lysine at 20-
30 Å of distance, or with DMSO as blank. Samples were loaded on a SDS-page gel 
and it was stained with silver staining to detect protein gel bands (Figure 8). In 
agreement with gel results, NAMPT WT dimerized as expected. Also, NAMPT 
S472A dimerized properly in a similar way to the WT protein. While, NAMPT 
S199/200A seems to be less cross-linked than NAMPT S472A and WT. 
Furthermore, the NAMPT S199/200A monomer band is more intensive than the 
S472A monomer band, further index of a less dimerization of S199/200A mutant. 
Our data suggest that S472A mutant can dimerize, in fact the mutations from serine 
472 to alanine is far from the interaction area between two NAMPT monomers. 
While S199/200A mutants cannot dimerize properly as expected, probably because 
we are replacing two amino acids in the dimerization area of NAMPT, making the 
dimerization of the dimer complex tough. All of these data find agreement with the 
results collected from the starvation localization experiment and the enzymatic assay 
performed.   
 
Chapter 6 
166 
 
 
Figure 8. Cross-linking data of NAMPT WT, NAMPT S199/200A and NAMPT S472A recombinant proteins. Each 
recombinant protein was incubated with BS3 cross-linker or DMSO. Proteins were detected by silver staining   
 
3. Significance: 
This work described novel NAMPT phosphorylated sites in mouse B16 WT cells.  
All the modified sites identified were quantified under different stimuli by LC-MS 
based proteomics. In according with the evidences proposed, the most promising 
sites were selected to be S472, S199 and S200. All of these residues were mutated 
in alanine the study the absence of phosphorylation in stable cells lines and in 
NAMPT recombinant proteins. The most outstanding finding is the S199/200A 
NAMPT mutant to be localized in nucleus, enzymatically inactive and not able to 
dimerize. Taken together, it could be hypnotized that an inactive NAMPT form is 
storage in nuclei as monomer with some still “unknown” role that has to be 
elucidated. 
At the same time, different mutations are object of this on-going project (e.g. S472D, 
S199A, S200A, S199D and S200D in first instance), with the aim to deeply 
understand the factors which regulate NAMPT functions and intracellular activities. 
- +
50 -
WT S472A
- +
S199200A
- +
75 -
BS3
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4. Material and Methods: 
Sample preparation for mass spectrometry analyses 
B16 cells were engineered to stably express NAMPT as an N-terminal GFP fusion 
protein. All B16 cells were normally cultured in DMEM supplemented with 10 % 
fetal bovine serum (FBS), 2 mg/mL glutamine, 10 U/mL penicillin and 100 lg/mL 
streptomycin. Typically, 1.5*106 cells were seeded and detached after 24 hours by 
trypsinization. When required, B16 cells were treated as following: (1) starvation 
condition: cells were grown for 8, 16 or 24 hours after adhesion in DMEM without 
FBS. (2) starvation condition +FBS: cells were grown for 24 hours after adhesion in 
DMEM without FBS, and then cells were grown for 2 hours after adhesion in DMEM 
with 10 % FBS. (3) Low glucose condition: cells were grown for 24 hours after 
adhesion in MEM with FBS. (4) UV condition: cells were treated for 20 seconds 
with UV light (254 nm) and were grown for 3 hours after adhesion in DMEM with 
FBS. (5) Kinase activators conditions: cells were treated for 1 hour with 20 µM 
phorbol-12-myristate-13-acetate (PMA) and 200 µM Forskolin. (6) Phosphatase 
inhibitors conditions: cells were treated for 2 hours with 100 µM NAF and 100 µM 
Na3VO4. 
After treatments, cells were harvested and lysed in lysing buffer 1 (10 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 0.5 % NP-40, 0.1 mM PMSF and an 
appropriate aliquots of the Calbiochem Protease Inhibitor Cocktail Set V) or lysis 
buffer 2 (100 mM Tris HCl pH 8.00, 150mM NaCl, 5mM EDTA, 5% glycerol (60%), 
0.1% NP40 (20%), 1mM DTT, 1 µg/ml Leupeptin, 1 µM Pepsidin, 1 mM ABESF, 
Phosphatase Inhibitors cocktail (BioGold), 250 U benzonase and 1 mM MgCl2 1M). 
After centrifuging at 13,000 g for 10 min at 4 °C, the supernatant was mixed with 
GFP-trap agarose beads (gta-100, Chromotek) and rotated at 4 °C O.N. Then, beads 
were pelleted and washed four times with ice-cold IP buffer (without phosphatase 
and protease inhibitors). The bound proteins were eluted in 0.2 M glycine pH 2.5. 
Protein samples were treated as following: an aliquot (̴ 30%) was treated with SDS-
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PAGE sample buffer by heating at 95 °C for 8 min. Protein samples were fractionated 
by 10% SDS–PAGE and stained with Colloidal Blue Staining. After dehydration, 
proteins in the gel slice were reduced by 10 mM Dithiothreitol and alkylated by 55 
mM 2-Iodoacetamide. After washing and dehydration with acetonitrile, the proteins 
were digested with trypsin and subjected to MS analyses. A second aliquot (̴ 70%) 
was treated with TCA and acetone performing several cycles of washing and 
centrifugations for precipitating proteins. Protein pellets were washed with acetone 
and digested with trypsin. Dried pellets were dissolved in 8 M urea / 100 mM Tris-
HCl, pH 8.5. Proteins were reduced with 5mM tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP, Sigma-Aldrich) and alkylated with 10mM iodoacetamide 
(Sigma-Aldrich). Proteins were digested overnight at 37 °C in 2 M urea / 100 mM 
Tris-HCl, pH 8.5, 1 mM CaCl2 with trypsin (Promega) in a ratio of 1:100 
(enzyme:protein). Digestion was stopped with formic acid, 5% final concentration. 
Debris was removed by centrifugation. Digests were desalted with Thermo Scientific 
C18 pipette tips prior injection in the LC-MS system. 
When required, samples were fractionated in nuclei and cytosol as following.  
After treatments, cells were harvested in trypsin and collected in ice. For 1 x 107 
cells, 200 µl of Buffer A (300mM Sucrose, 10mM Hepes10mM KCl, and 2mM 
MgCl2 and 0.1 mM PMSF and an appropriate aliquots of the Calbiochem Protease 
Inhibitor Cocktail Set V) were added to the cells precipitate. Subsequently, 0.15% 
NP-40 was added. The resulting solution was centrifuged at 13,000g for 15 min at 4 
°C. The supernatant was collected as cytosol fraction. 
The pellet was washed with 500 µl of Buffer B (50mM Hepes, 400mM NaCl, 1mM 
EDTA and 1mM EGTA and 0.1 mM PMSF and an appropriate aliquots of the 
Calbiochem Protease Inhibitor Cocktail Set V). Pellet was resuspended in 360 µl 
buffer B and sonication cycles were repeated until the lysis of nuclear membranes. 
The intracellular content was maintained at 4°C for 45 min and shaked for 10 sec 
each 5 minutes. Centrifuge samples at 13,000g for 15 min at 4 °C. The supernatant 
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was collected as nuclei fraction. Then, the sample preparation continues with GFP-
NAMPT immunoprecipitation as reported previously. Afterwards, the protein pellets 
were collected as described early in 8 M urea / 100 mM Tris-HCl, pH 8.5 and 
digested, desalted, and LC-MS analysed. 
 
LC-MS/MS analysis 
Phosphorylated peptides were subjected to LC–MS/MS analysis using an Dionex 
ultimate 3000 ultra-high pressure liquid chromatography system (Thermo Scientific) 
connected to an Orbitrap-Fusion-Tribrid mass spectrometer (Thermo Scientific) with 
a Phoenix Nimbus (Phoenix S&T) ion source. Data dependent acquisition (DDA) 
and parallel reaction monitoring (PRM) approaches were chosen for peptides 
identification and label free quantitation. 
For DDA, peptides were eluted on a reversed phase C18 column (250 mm × 75 mm 
i.d., 3 μm p.d.) by a gradient mode constituted of solvent A (0.1% formic acid, 3% 
DMSO in water) and B (0.1% formic acid, 3% DMSO in ACN) at a flow rate of 200 
nl min-1: 1–5.5% solvent B in 5 min; 5.5–27.5% solvent B in 123 min; 27.5–35% 
solvent B in 7 min; 35–80% solvent B in 1 min and kept 2 min before the re-
conditioning of the column. The total analysis time for each sample was 140 min.  In 
survey scans, full-scan MS spectra were acquired by the Orbitrap analyser at a 
resolution of 120,000, scanning from m/z 400 to m/z 1600. AGC target was 2e5 and 
maximum injection time was 100 ms. MS2 quadrupole selection isolation window 
was m/z 1.6. The top speed mode was selected. MS/MS spectra were detected using 
Orbitrap analyser at the resolution of 15,000. AGC target was 5.0e4 and the 
maximum injection time was 35 ms. The normalized HCD energy was set at 35%. 
For PRM, the mass spectrometry system and the chromatography gradient are 
described as for DDA. The resolution of MS1 full scan was set to 50,000, scanning 
from m/z 100 to m/z 2000; AGC target was 5e4 and the maximum injection time is 
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set to 100 ms. Precursors are selected by the quadrupole mass analyser using an 
isolation window set to 1.6 Da. The normalized HCD energy was set at 35%. 
 
MS data processing 
For the identification of phosphorylated peptides, Raw DDA MS files were 
processed using MS-GF+ search algorithm34. NAMPT phosphorylated peptides were 
were identified using a target-decoy approach by searching all MS/MS spectra 
against a forward/reversed mouse database and filtered by using a percolator derived 
q value of 0.01 at peptide spectral level. Carbamidomethylation of cysteines was 
selected as the fixed modification and the phosphorylation (STY) as the variable 
modification. The database search was performed with an initial precursor ion 
tolerance of 15 p.p.m., MS/MS tolerance at 0.02 Da, and two missed cleavages are 
allowed. Phosphosite localization was assessed using PhosphoRS algorithm35 and 
the phosphopeptide containing the residues with phosphor-probability greater than 
0.95 were used for further quantification. Label free quantitation was performed with 
skyline (version 3.7). The quantification was performed using PRM data at the MS2 
level36, which is widely used for phosphopeptide quantification37,38,39. The intensity 
of phosphopeptide was derived from the peak area of specific daughter ion, and all 
Skyline integrated PRM data analysis were manually checked to validate peak 
Selection. The intensity of the phosphopeptide detected was normalized against the 
daughter ion peak area of NAMPT unphosphorylated peptides, chosen as control to 
correct sample variations. 
 
Production of NAMPT recombinant proteins  
Wild-type murine full-length NAMPT (ORF GenBank BC018358) was cloned in 
pET28a (NdeI/EcoRI). Mutants NAMPT S472A and S199200A were obtained by 
mutagenesis (QuikChange Lightning Site-Directed Mutagenesis Kit, Agilent 
Technoligoes) from NAMPT WT by using the following primers: 5’-
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TTTTTCTGACTTCATCAAATGCGTAGCTTTTTGTCACCTTCCC (fw) and 5’-
GGGAAGGTGACAAAAAGCTACGCATTTGATGAAGTCAGAAAAA (rev) for 
S472A mutant and 5’-CCAGCAGTCTCTTGCGCAGCGACTCCTCTGTAACCA 
(fw) and 3’- TGGTTACAGAGGAGTCGCTGCGCAAGAGACTGCTGG (rev) for 
S199200A mutant. 
All recombinant NAMPTs were expressed in E. Coli BL21(D3) (induction with 
IPTG 0.5 mM for 3 h at 25°C) and purified by His-tag affinity chromatography with 
NiNTA Superflow resin (Qiagen). Human recombinant NAMPT was commercially 
available (AG-40A-0018AA-C500, AdipoGen Inc; Seoul Korea). Correct insertion 
and sequence were confirmed by sequencing. 
 
Creation of stable mouse B16 GFP-nampt cell lines 
Wild-type murine full-length NAMPT (ORF GenBank BC018358) was cloned in 
pLV-GFP-NAMPT-IRES-GFP (Bicistronic vector). Mutants NAMPT S472A and 
S199200A were obtained by mutagenesis (QuikChange Lightning Site-Directed 
Mutagenesis Kit, Agilent Technoligoes) from NAMPT WT by using the following 
primers: 5’-TTTTTCTGACTTCATCAAATGCGTAGCTTTTTGTCACCTTCCC 
(fw) and 5’-
GGGAAGGTGACAAAAAGCTACGCATTTGATGAAGTCAGAAAAA (rev) for 
S472A mutant and 5’-CCAGCAGTCTCTTGCGCAGCGACTCCTCTGTAACCA 
(fw) and 3’- TGGTTACAGAGGAGTCGCTGCGCAAGAGACTGCTGG (rev) for 
S199200A mutant. 
B16 GFP-NAMPT cell line was cloned in the pLV-IRES-GFP bicistronic vector. 
Correct insertion and sequence were confirmed by sequencing. The lentiviral 
particles were produced as described elsewhere40 in HEK293T cells transfected with 
pMDLg/pRRE, pMD2.VSVG, pRSV-Rev and pLV-GFP-NAMPT-IRES-GFP. 
Briefly, after 48 h, cell medium was collected, filtrated and centrifuged for 1 h 30 
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min at 100000 x g. The viral particles, corresponding to the pellet fraction, were 
resuspended and used to infect B16 cells, after virus titration.  
Stable B16 GFP-NAMPT S472A and S199/200A cell lines were created, and GFP-
NAMPT expression was monitored with immunocytochemistry and Western blot.  
Immunocytochemistry experiment 
For immunocytochemistry experiment, cells were fixed after treatments in 4% 
formaldehyde. Subsequently, nuclei were stained with DRAQ5 (Thermo Fisher 
Scientific). Fluorescence images were acquired using a Leica (Leica Microsystems, 
Wetzlar, Germany) epifluorescent microscope equipped with S Fluor 40x/1.3 
objective using METAMORPH (Molecular Devices, Sunnyvale, CA, USA) 
software. 
 
Coupled enzymatic assay for NAMPT activity 
Wild type Mus musculus NAMPT was recombinantly expressed in bacteria and 
purified to homogeneity following established procedures41. Assay was conducted as 
described previously29, with some modifications. The reactions were run at 37 °C, 
with 1µg, 2µg,  3µg,  5µg or  10µg of  NAMPT, reacted in a 200 µL sample 
containing 30 mM HEPES pH 7.5, 1 mM NAM, 0.2 mM PRPP, 1 mM ATP, 25 mM 
MgCl2, 1 mM DTT, 75 mM ethanol, 30 mM semicarbazide, 5 mU mNMNAT-3 (2 
µg), 2.5 U ADH (11 µg), and 110 µg BSA. NADH formation was monitored over a 
period of 3 hours (each 2.5 min) by emission of fluorescence at 455 nm upon 
excitation at 340 nm. 
 
NAMPT dimer cross-linking experiment 
Recombinant NAMPT WT, S472A or S199200A purified proteins were mixed in 
reconstitution buffer (50 mM NaH2PO4 pH 7.5, 250 mM NaCl, 0.25 mM 
Dithiothreitol) and maintained in ice for 20 min. Afterwards, 
bis(sulfosuccinimidyl)suberate (BS3) was added to the sample to a final 
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concentration of 100 µM. Sample was kept in ice for two hours. Cross-linking 
reaction was quenched with 50 mM Tris- HCl pH 7.5 and left 15 min at 25°C in 
agitation. The resulting sample was treated with SDS-PAGE sample buffer by 
heating at 95 °C for 8 min. Protein samples were fractionated by 10% SDS–PAGE 
and stained with Silver Staining (Thermo Fisher Scientific). 
 
Western Blotting 
Proteins extracted were quantified by Bradford Protein Assay, separated on SDS-
PAGE, blotted onto a nitrocellulose membrane, and stained with monoclonal 
antibodies specific for GFP, Vinculin and H2A. 
 
Statistical analysis 
All data represent the mean and SD of at least 2 biological independent experiments. 
T test statistical analysis was carried out by PRISM program. A p value ≤ 0.05 was 
considered as significant and indicated in figures with asterisks (*).  
 
Cell culture 
All B16 cells were normally cultured in DMEM supplemented with 10 % fetal 
bovine serum (FBS), 2 mg/mL glutamine, 10 U/mL penicillin and 100 lg/mL 
streptomycin. Typically, 1.5×106 cells were seeded and detached after 24 hours by 
trypsinization.  
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Discussion: 
Liquid chromatography tandem mass spectrometry has been a revolutionary 
technique since the development of an ionization interface between the liquid 
chromatography and the mass spectrometry in the 80s. In the last decades, novel 
instruments with outstanding performance and new updates made the LC-MS an 
essential tool with a multidisciplinary attitude in the scientific research. 
As claimed by this thesis, a lot of research fields were positively affected by the 
impact of the LC-MS. Not only chemistry, composed by all its branches (e.g. the 
analytical, organic and medicinal chemistry) but also biology (e.g. in vitro and in 
vivo metabolism and post translational modifications in proteins studies). 
Assembling different liquid chromatography apparatus with various MS analyzers 
through a discrete choice of ionization sources, it is possible to build up instruments 
able to perform qualitative or quantitative analysis. Nowadays, hybrids LC-MS 
equipped with at least two MS analysers are the recent trend. They confer to the 
scientist the possibility to overcome a tricky situation with only one instrument 
exploiting all of its functions.  
Against this backdrop, I focused my PhD project mainly on the developing of LC-
MS methods useful to carry out targeted and untargeted analysis.  
 
The first project was about the identification and characterization of degradation 
compounds of Troxerutin. Starting from Troxerutin mixture, the three mains 
hydroxyethyl derivates were purified and underwent to stability studies following 
the ICH guidelines. The main achievement was to identify and characterize three 
degradation products (D1, D2 and D3), and to confer to D1 the role of stability 
indicator compound of Troxerutin.  
Subsequently, the LC-MS method used for screening all of the degradation 
conditions, was transferred on a LC-UV instrument. It was firstly adapted and 
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optimized for developing and afterwards to validate a stability-indicating method for 
Troxerutin pharmaceutical dosage forms (ampoules, capsules and coated tablets).  
In these studies, the LC-ESI-MS was constituted by an HPLC operating at micro-
flows and an ion trap mass spectrometer. The LC component of the method was 
constituted by a basic elution on a C18 column functionalized to maintain its integrity 
in a wide range of pH till basic values. Indeed, the ion trap as MS analyzer could be 
considered one of the first choices to run these experiments. The MS operated in full 
MS, MS2 and MS3 for the identification and to characterize hydroxyethylrutosides 
purified products and its degradation compounds. 
 
Secondly, we applied the LC-MS techniques for quantitative analysis of endogenous 
small molecules in biological matrices (e.g. cells, plasma and extracellular cells 
culture media).  
 
The first bioanalytical project raised from the serendipity finding of an unpredicted 
reaction product formed in vitro by NAMPT. The product was identified by cross 
analysis, among which even the mass spectrometry was involved, to be adenosine 
5’-tetraphosphate (Ap4). Ap4 is formed from two molecules of ATP by a new and 
unpredicted NAMPT phosphor-transfer reaction. This reaction was deeply studied 
and characterized through in vitro experiments.  
Nevertheless, in order to evaluate a correlation between NAMPT and Ap4 
production in vivo, the intracellular content of mammalian cells was analyzed by LC-
MS. Four engineered B16 WT cells types were studied for intracellular levels of 
Ap4, ATP, ADP, Nam, NMN and NAD. 
Quantitative results showed that NAMPT is an intracellular source of Ap4, even if 
we cannot rule out the possibility that other enzymes could contribute with its 
synthesis. Also, relevant information about ATP intracellular levels, ATP/ADP ratio 
and phosphoribosyltransferase reaction data were collected for each cell line. 
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Moreover, Ap4 and NMN intracellular levels under metabolic perturbation 
conditions (oxidative, low-glucose and serum-free) were described confirming and 
integrating the data already collected and discussed. 
Finally, we measured Ap4, NMN (by LC-MS) and NAMPT (via ELISA assay) 
extracellular levels in mouse plasma. Not surprisingly, quantitative data reported a 
correlation between Ap4 and NAMPT levels and Ap4 and ATP concentrations. 
Taken together these data we confirmed the activity of NAMPT phospho-transfer 
reaction in mouse plasma. 
All of these results were obtained by collecting intracellular contents and mouse 
plasma samples and performing a sample preparation based on the protein 
precipitation with organic solvents. Two sample preparation methods were 
developed, one for each matrix. In fact, the matrices involved in this project have 
different chemical compositions in term of proteins, lipids, salts and other small 
molecules. We could also add that each sample preparation method was optimized 
to find a compromise between obtaining a satisfactory average recovery value per 
each analyte and a simple, rapid and easy to scale up sample preparation protocol to 
huge batches.  
Then, we injected concentrated samples in the LC-MS. The LC component of the 
method was carried out using a Luna HILIC stationary phase, essential for increasing 
the retention of polar small molecules. An isocratic elution was developed to avoid 
the increment or suppression of the ionization signal during the LC-MS run, due 
probably to the components still present in the matrix after treatments (e.g. amino 
acids, sugars, lipids and other small molecules). 
The MS system operated in both positive and negative ionization mode, according 
to the chemical features of each compound. Each analyte was monitored in SRM or 
MRM mode except for Nam that was monitored in MS2 mode cause its low 
molecular weight which causes the impracticability to monitor a stable MS/MS 
fragmentation reaction. 
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The quantitative data were obtained using an external calibration method due to 
presence of the analytes of interest in all the biological matrices in physiological 
conditions. In fact, it was not possible to have both matrices free of Ap4 and other 
analytes.  
 
The second bioanalytical project was part of a huge study about the evaluation of the 
ability of trazodone to promote adult neural differentiation of murine and human 
Neural Progenitor Cells (NPC). The LC-MS found application in order to assess 
whether proneurogenic effect of TZD correlates with an increase of serotonin 
extracellular levels. Data showed that there are not statistically significant 
differences between serotonin extracellular levels in cells treated with trazodone vs 
untreated. Nevertheless, thanks to the LC-MS analysis, we demonstrated that 
ahNPCs cells does express 5-HTT receptor. 
The LC-MS method developed consisted in a targeted method aimed to the 
quantification of serotonin in extracellular culture media.  
The sample preparation consisted in protein precipitation approach of the media 
collected after cell treatments. In this case, it was important to have satisfactory 
recovery results to avoid analyte lost during this step, because serotonin levels are in 
general low in the samples available.  
For this method, the LC component was optimized in an isocratic elution on a C18 
HILIC column, really useful for polar compounds. We did not observe matrix effect 
during the serotonin detection. Moreover, the combination of stationary and mobile 
phase developed, allowed the best response in terms of retention time stability and 
peak shape of our compound of interest. 
While, the MS worked in positive ionization, monitoring serotonin in SRM mode, 
one of the golden standard acquisition mode for quantitative LC-MS studies.  
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The third application of liquid chromatography tandem mass spectrometry technique 
described in this thesis is the LC-MS based proteomics. The project born from a quite 
surprisingly gap of knowledge regarding Nicotinamide Phosphoribosyltransferase 
(NAMPT). NAMPT is well described as a rate-limiting enzyme in NAD synthesis, 
which its high levels are related to prognosis and overall survival.  
However, it has never been reported in literature studies related to NAMPT and its 
phosphorylation, one of the most common post translational modifications. 
We identified and label free quantified thirteen phosphorylated sites on NAMPT in 
murine B16 WT cells treated in four conditions.  
The identification and label-free quantitation of STY phosphorylated sites was 
performed starting from the development of an immunoprecipitation protocol 
suitable for LC-MS analysis. A nano-UHPLC coupled with an Orbitrap Fusion 
Lumos Tribrid MS was used in DDA (for qualitative analysis) or in PRM mode (for 
quantitative analysis). Data analysis was performed to identify, filter the false 
positive identifications and label-free quantify each site modified. 
Based on quantitative proteomics analysis, S199, S200 and S472 NAMPT 
phosphorylated sites resulted the most abundant and by mutagenesis we are studying 
at biological level the contribution of each phosphorylation.  
Different experiments were performed and as preliminary data, the double mutation 
of S199/200A showed the most interesting results vs NAMPT WT. It seems that this 
NAMPT mutant cannot dimerize, so it is not enzymatically active and localize in 
nuclei of B16 cells.  
The investigation of individual S199A and S200A is on-going. Moreover, the 
characterization at biological level of phospho-mimic mutants of S472, S199 and 
S200 and other phosphorylation sites (e.g. T406) is planned in the next future. 
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In conclusion, in these three years of PhD program, the versatility, reproducibility 
and robustness of LC-MS analysis has been described and demonstrated through 
chemical and biological projects:  
(1) Troxerutin degradation pathway was elucidated through the identification and 
characterization of troxerutin degradation products. 
(2) Ap4 and NAMPT related analytes were quantified in B16 WT cells and mouse 
plasma. 
(3) Serotonin was quantified in extracellular culture media of murine neural 
progenitor cells. 
(4) Thirteen NAMPT phosphorylated sites were identified and label free quantified 
in murine B16 WT cells. Preliminary data about the biological characterization of 
NAMPT modified sites were proposed. 
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